CORTEX PHARMACEUTICALS INC/DE/ (Form: 8-K, Received: 03/24/2014 17:23:39)

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

Current Report

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 18, 2014

CORTEX PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware	1-16467	33-0303583
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S Employer Identification No.)

126 Valley Road, Suite C Glen Rock, New Jersey	07452
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code: (949) 727-3157

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 1.01 Entry into a Material Definitive Agreement.

Securities Purchase Agreement

On March 18, 2014, Cortex Pharmaceuticals, Inc. (the “Company”) entered into Securities Purchase Agreements (the “Securities Purchase Agreements”) with various accredited investors (each, a “Purchaser”), pursuant to which the Company sold an aggregate of 753.22 shares of its Series G 1.5% Convertible Preferred Stock, par value $0.001 per share (the “Series G Preferred Stock”) for a purchase price of $1,000 per share, or an aggregate Purchase Price of $753,220 (the “Purchase Price”). This financing represents the initial closing on a private placement of up to $1,500,000 (the “Private Placement”). One or more additional tranches in the Private Placement may close in the near future. The Purchasers in the initial tranche of the Private Placement consisted of (i) Arnold S. Lippa, the Company’s Chairman, Chief Executive Officer and a member of the Company’s Board of Directors, who had not previously owned stock in the Company and who invested $250,000, and (ii) new investors. Neither the Series G Preferred Stock nor the underlying shares of common stock have any registration rights. All of the Purchasers are, and any Purchasers in any future tranches shall be, accredited investors.

The stated value of the Series G Preferred Stock is $1,000 per share, and the initial conversion price is $0.0033. Accordingly, at the option of the holder, each share of Series G Preferred Stock is convertible commencing on the date that is 60 calendar days after the date on which the last share of Series G Preferred Stock is issued pursuant to a Purchase Agreement, into 303,030.3 shares of common stock. The 753.22 shares of Series G Preferred Stock sold in the Private Placement to date are convertible into 228,248,483 shares of common stock. The Company had 144,041,558 shares of common stock issued and outstanding immediately prior to the closing of the Private Placement referred to herein. The details of the Series G Preferred Stock are described more fully in Item 5.03 of this Current Report on Form 8-K and are qualified in their entirety by reference to the Certificate of Designation for the Series G Preferred Stock, which is filed as Exhibit 3.1 to this Current Report on Form 8-K. As described in the Stock Purchase Agreement, purchasers of the Series G Preferred Stock have executed written consents in favor of (i) approving and adopting an amendment to the Company’s certificate of incorporation that increases the number of authorized shares of the Company to 1,405,000,000, 1,400,000,000 of which are shares of common stock and 5,000,000 of which are shares of preferred stock, and (ii) approving and adopting the Cortex Pharmaceuticals, Inc. 2014 Equity, Equity-Linked and Equity Derivative Incentive Plan.

The placement agents and selected dealers in connection with the Private Placement (each a FINRA registered broker-dealer) received cash fees totaling $3,955 as compensation and warrants (“Placement Agent Warrants”) totaling 5.6365% of the shares of common stock into which the Series G Preferred Stock may convert, exercisable for five years at a price that is 120% of the conversion price at which the Series G Preferred Stock may convert into the Company’s common stock, par value $0.001. The shares of Series G Preferred Stock were offered and sold without registration under the Securities Act of 1933, as amended (the “Securities Act”) in reliance on the exemptions provided by Section 4(a)(2) of the Securities Act as provided in Rule 506 of Regulation D promulgated thereunder. The shares of Series G Preferred Stock and the Company’s common stock issuable upon conversion of the shares of Series G Preferred Stock have not been registered under the Securities Act or any other applicable securities laws, and unless so registered, may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the Securities Act.

This description of the Securities Purchase Agreements does not purport to be complete and is qualified in its entirety by reference to the form of Securities Purchase Agreement, a copy of which is attached to this Current Report on Form 8-K as Exhibit 10.1 and is incorporated herein by reference.

Cortex Pharmaceuticals, Inc. 2014 Equity, Equity-Linked and Equity Derivative Incentive Plan

In connection with the Private Placement, the stockholders of the Company holding a majority of the votes to be cast on the issue, approved the adoption of the Cortex Pharmaceuticals, Inc. 2014 Equity, Equity-Linked and Equity Derivative Incentive Plan (the “Plan”), which had been previously adopted by the Board of Directors of the Company, subject to stockholder approval. The Plan permits the grant of options and restricted stock with respect to up to 105,633,002 shares of common stock, in addition to stock appreciation rights and phantom stock, to directors, officers, employees, consultants and other service providers of the Company. A copy of the Plan is attached as Exhibit 10.2 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 3.02 Unregistered Sales of Equity Securities.

The information provided in response to Item 1.01 of this report is incorporated by reference into this Item 3.02. The investors in the Private Placement made representations to the Company that they met the accredited investor definition of Rule 501 of the Securities Act, and the Company relied on such representations. The offer and sale of the Series G Preferred Stock and Placement Agent Warrants in the offering were made in reliance on the exemption from registration afforded by Section 4(a)(2) of the Securities Act as provided in Rule 506(b) of Regulation D promulgated thereunder. The Private Placement was not conducted in connection with a public offering, and no public solicitation or advertisement was made or relied upon by any investor in connection with the offering. This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall such securities be offered or sold in the United States absent registration or an applicable exemption from the registration requirements.

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

On March 14, 2014, the Company filed a Certificate of Designation, Preferences, Rights and Limitations, (the “Certificate of Designation”) of its Series G Preferred Stock with the Secretary of State of the State of Delaware to amend the Company’s certificate of incorporation. The Certificate of Designation sets forth the preferences, rights and limitations of the Series G Preferred Stock. As provided in the Company’s certificate of incorporation, the filing of the Certificate of Designation was approved by the Company’s Board of Directors. The following is a summary of the rights, privileges and preferences of the Series G Preferred Stock:

Number of Shares: The number of shares designated as Series G Preferred Stock is 1,700 (which shall not be subject to increase without the written consent of a majority of the holders of the Series G Preferred Stock or as otherwise set forth in the Certificate of Designation).

Stated Value: The initial Stated Value of each share of Series G Preferred Stock is $1,000.

Dividend : The Company shall pay a stated dividend on the Series G Preferred Stock at a rate per share (as a percentage of the Stated Value per share) of 1.5% per annum, payable quarterly within 15 calendar days of the end of each fiscal quarter of the Company, in duly authorized, validly issued, fully paid and non-assessable shares of Series G Preferred Stock, which may include fractional shares of Series G Preferred Stock.

Voluntary Conversion: The Series G Preferred Stock shall be convertible, beginning 60 days after the last share of Series G Preferred Stock is issued in the Private Placement, at the option of the holder, into common stock at the applicable conversion price, at a rate determined by dividing the Stated Value of the shares of Series G Preferred Stock to be converted by the conversion price, subject to adjustments for stock dividends, splits, combinations and similar events as described in the form of Certificate of Designation. The stated value of the Series G Preferred Stock is $1,000 per share, and the initial conversion price is $0.0033. Accordingly, at the option of the holder, each share of Series G Preferred Stock is convertible commencing on the date that is 60 calendar days after the date on which the last share of Series G Preferred Stock is issued pursuant to a Purchase Agreement, into 303,030.3 shares of common stock. In addition, the Company has the right to require the holders of the Series G Preferred Stock to convert such shares into common stock under certain enumerated circumstances.

Mandatory Conversion : Upon either (i) a Qualified Public Offering (as defined in the Certificate of Designation) or (ii) the affirmative vote of the holders of a majority of the Stated Value of the Series G Preferred Stock issued and outstanding, all outstanding shares of Series G Preferred Stock, plus all accrued or declared, but unpaid, dividends thereon, shall mandatorily be converted into such number of shares of common stock determined by dividing the Stated Value of such Series G Preferred Stock (together with the amount of any accrued or declared, but unpaid, dividends thereon) by the Conversion Price (as defined in the Certificate of Designation) then in effect. If not earlier converted, the Series G Preferred Stock shall be redeemed by conversion on the two year anniversary of the date the last share of Series G Preferred Stock is issued in the Private Placement at the then applicable Conversion Price.

Voting Rights: Except as described in the Certificate of Designation, holders of the Series G Preferred Stock will vote together with holders of the Company common stock on all matters, on an as-converted to common stock basis, and not as a separate class or series (subject to limited exceptions).

Liquidation Preferences: In the event of any liquidation or winding up of the Company prior to and in preference to any Junior Securities (including common stock), the holders of the Series G Preferred Stock will be entitled to receive in preference to the holders of the Company common stock a per share amount equal to the Stated Value, plus any accrued and unpaid dividends thereon.

THE FOREGOING SUMMARY OF THE PREFERENCES, RIGHTS, AND LIMITATIONS OF THE SERIES G PREFERRED STOCK IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO THE CERTIFICATE OF DESIGNATION FOR THE SERIES G PREFERRED STOCK, WHICH IS FILED AS EXHIBIT 3.1 TO THIS CURRENT REPORT ON FORM 8-K.

Item 5.07 Submission of Matters to a Vote of Security Holders.

Effective upon completion of the Private Placement, the holders of the Series G Preferred Stock voted by written consent to approve and adopt (i) an amendment to the certificate of incorporation of the Company (the “Amendment”) to increase the number of authorized shares of the Company to 1,405,000,000, in the form that had previously been approved by the Board of Directors and provided to holders of the Series G Preferred Stock, and (ii) the Cortex Pharmaceuticals, Inc. 2014 Equity, Equity-Linked and Equity Derivative Incentive Plan (the “Plan”), in the form that had previously been approved by the Board of Directors and provided to holders of the Series G Preferred Stock. Since holders of the Series G Preferred Stock are entitled to 303,030 votes per share prior to their right to convert, such votes by the holders of the Series G Preferred Stock were sufficient to approve and adopt the Amendment and the Plan by written consent.

The Company anticipates filing the Amendment to increase the number of authorized shares in the near future and reporting that filing appropriately on a subsequent Current Report on Form 8-K. The Cortex Pharmaceuticals, Inc. 2014 Equity, Equity-Linked and Equity Derivative Incentive Plan is filed as Exhibit 10.2 to this Current Report on Form 8-K.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits.

A list of exhibits required to be filed as part of this report is set forth in the Exhibit Index, which is presented elsewhere in this document, and is incorporated herein by reference.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: March 24, 2014	CORTEX PHARMACEUTICALS, INC.

	By:	/s/ Arnold S. Lippa
		Arnold S. Lippa
		President and Chief Executive Officer

EXHIBIT INDEX

Exhibit Number		Exhibit Description
3.1		Certificate of Designation, Preferences, Rights and Limitations of Series G 1.5% Convertible Preferred Stock
10.1		Form of Securities Purchase Agreement
10.2		Cortex Pharmaceuticals, Inc. 2014 Equity, Equity-Linked and Equity Derivative Incentive Plan

Exhibit 3.1

CORTEX PHARMACEUTICALS, INC.

CERTIFICATE OF DESIGNATION,

PREFERENCES, RIGHTS AND LIMITATIONS

SERIES G 1.5% CONVERTIBLE PREFERRED STOCK

PURSUANT TO SECTION 151

OF THE DELAWARE GENERAL CORPORATION LAW

Cortex Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware (the “ Corporation ”), hereby certifies that the Board of Directors of the Corporation (the “ Board of Directors ” or the “ Board ”), pursuant to authority of the Board of Directors as required by Section 151 of the Delaware General Corporation Law, and in accordance with the provisions of its Certificate of Incorporation and Bylaws, each as amended and restated through the date hereof, has and hereby authorizes a series of the Corporation’s previously authorized preferred stock, and hereby states the designation and number of shares, and fixes the relative rights, preferences, privileges, powers and restrictions thereof, as follows:

Section 1. Designation and Amount . The designation of this series, which consists of up to 1,700 shares of preferred stock (which shall not be subject to increase without the written consent of holders the Series G Preferred Stock, as hereinafter defined (each, a “ Holder ” and collectively, the “ Holders ”) holding greater than 50% of the Series G Preferred Stock then outstanding), is the Series G 1.5% Convertible Preferred Stock (the “ Series G Preferred Stock ”) with a par value of $0.001 per share and a stated value of One Thousand Dollars ($1,000) per share (the “ Stated Value ”).

Section 2. Certain Definitions . For purposes of this Certificate of Designation, in addition to the other terms defined herein, the following terms shall have the following meanings:

“ Approved Stock Plan ” means any employee benefit plan which has been approved by the Board of Directors of the Corporation, pursuant to which the Corporation’s securities may be issued to any employee, consultant, officer or director for services provided to the Corporation.

“ Business Day ” means any calendar day except Saturday, Sunday, or any calendar day which shall be a federal legal holiday in the United States or any calendar day on which banking institutions in the State of New York are authorized or required by law or other governmental action to close.

“ Change of Control Transaction ” means after giving effect to the issuance of the Series G Preferred Stock as provided for in the Purchase Agreement and any conversion thereof, whether such conversion has actually occurred or not, (i) an acquisition after the date hereof by an individual, legal entity or “group” (as described in Rule 13d-5(b)(1) promulgated under the Exchange Act) of effective control (whether through legal or beneficial ownership of capital stock of the Corporation, by contract or otherwise) of in excess of 50% of the voting securities of the Corporation (other than by means of conversion or exercise of Series G Preferred Stock issued), or (ii) the Corporation merges into or consolidates with any other Person, or any Person merges into or consolidates with the Corporation and, after giving effect to such transaction, the stockholders of the Corporation immediately prior to such transaction own less than 50% of the aggregate voting power of the Corporation or the successor entity of such transaction, or (iii) the Corporation sells or transfers all or substantially all of its assets to another Person and the stockholders of the Corporation immediately prior to such transaction own less than 50% of the aggregate voting power of the acquiring entity immediately after the transaction, or (iv) the execution by the Corporation of an agreement to which the Corporation is a party or by which it is bound, providing for any of the events set forth in clauses (i) through (iii) above.

“ Closing Date ” means each day when the Purchase Agreement has been executed and delivered by the applicable parties thereto, along with the full amount of the purchase consideration.

“ Commission ” means the United States Securities and Exchange Commission.

“ Common Stock ” means the Corporation’s common stock, par value $0.001 per share, and stock of any other class of securities into which such securities may hereafter be reclassified or changed into.

“ Common Stock Equivalents ” means any securities of the Corporation or the Subsidiaries which would entitle the holder thereof to acquire at any time Common Stock, including, without limitation, any debt, preferred stock, rights, options, warrants or other instrument that is at any time convertible into or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.

“ Conversion Shares ” means, collectively, the shares of Common Stock issuable upon conversion of the shares of Series G Preferred Stock in accordance with the terms hereof.

“ DGCL ” means the Delaware General Corporation Law, as amended, or any successor law, and the rules and regulations promulgated thereunder.

“ Exchange Act ” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.

“ Exempt Issuance ” means the issuance of (a) securities of the Corporation issued pursuant to any Approved Stock Plan, (b) securities issued upon the exercise of any securities issued hereunder or any other securities exercisable or exchangeable for or convertible into shares of Common Stock issued and outstanding on the date of the Purchase Agreement, (c) securities issued pursuant to acquisitions or strategic transactions, provided that any such issuance shall only be to an entity that is, itself or through its subsidiaries, an operating company in a business synergistic with the business of the Corporation and shall provide to the Corporation additional benefits in addition to the investment of funds, but shall not include a transaction in which the Corporation is issuing securities primarily for the purpose of raising capital or to an entity whose primary business is investing in securities and (d) securities issued in connection with any bona fide commercial loan or debt transaction with third persons, provided that the primary purpose of such transaction is not to raise equity capital and is approved by the Corporation’s Board of Directors.

“ Junior Securities ” means the Series B Preferred Stock, the Common Stock and all other Common Stock Equivalents of the Corporation other than those securities which are explicitly senior or pari passu to the Series G Preferred Stock in dividend rights or liquidation preference.

“ Liquidation ” means a liquidation of the Corporation in accordance with Section 5 .

“ Mandatory Conversion ” means a conversion of the Series G Preferred Stock by the Corporation in accordance with Section 6(c) .

“ Mandatory Redemption ” means a redemption of the Series G Preferred Stock by the Corporation in accordance with Section 6(d) .

“ Mandatory Redemption Date ” means the two year anniversary of the date on which the last share of the Series G Preferred Stock is issued pursuant to the Purchase Agreement.

“ Original Issue Date ” means the date of the issuance of any shares of the Series G Preferred Stock regardless of the number of transfers of any particular shares of Series G Preferred Stock and regardless of the number of certificates which may be issued to evidence such Series G Preferred Stock.

“ Purchase Agreement ” means the initial Stock Purchase Agreement or subsequent Purchase Agreements, as applicable, addressing the purchase of the Series G Preferred Stock, to which the Corporation and the original Holders are parties, each as amended, modified or supplemented from time to time in accordance with its terms.

“ Qualified Public Offering ” means the consummation of any offering of equity securities, or debt securities convertible into equity securities, with aggregate gross proceeds to the Corporation of not less than $2,000,000.

“ Series B Preferred Stock ” means the Corporation’s series B preferred stock, par value $0.001 per share.

“ Subsidiary ” means any direct or indirect subsidiary of the Corporation.

“ Trading Day ” means a day on which the New York Stock Exchange is open for business.

Section 3. Dividends in Cash or in Kind.

(a) Holders shall be entitled to receive, and the Corporation shall pay, cumulative dividends at the rate per share (as a percentage of the Stated Value per share) of 1.5% per annum , payable quarterly within 15 calendar days of the end of each fiscal quarter of the Company, (each such date, a “ Dividend Payment Date ”) in duly authorized, validly issued, fully paid and non-assessable shares of Series G Preferred Stock, which may include fractional shares of Series G Preferred Stock. The dividend to be paid in the first quarter after closing and the last quarter prior to conversion may be partial periods. Dividends on the Series G Preferred Stock shall be calculated on the basis of a 360-day year, consisting of twelve 30 calendar day periods, shall accrue daily commencing on the Original Issue Date, and shall be deemed to accrue from such date whether or not earned or declared and whether or not there are profits, surplus or other funds of the Corporation legally available for the payment of dividends.

(b) So long as any Series G Preferred Stock remains outstanding, neither the Corporation nor any Subsidiary shall directly or indirectly pay or declare any dividend or make any distribution upon, nor shall any distribution be made in respect of, any Junior Securities as long as any dividends due on the Series G Preferred Stock remain unpaid, nor shall any monies be set aside for or applied to the purchase or redemption (through a sinking fund or otherwise) of any Junior Securities.

Section 4. Voting Rights . Except as otherwise provided herein and as otherwise prohibited by law, the Series G Preferred Stock shall have the following voting rights: (i) at any time prior to the date the Series G Preferred Stock is convertible into Common Stock, the Series G Preferred shall be entitled to 303,030 votes per share, and (ii) at any time on or after the date the Series G Preferred Stock is convertible into Common Stocking each share of Series G Preferred Stock shall have the voting rights it would have on an as converted basis. Without limiting the generality of the foregoing sentence, voting rights shall also be subject to the restrictions of Section 8 .

To the extent that under the DGCL the vote of the holders of the Series G Preferred Stock, voting separately as a class or series, as applicable, is required to authorize a given action of the Corporation, the affirmative vote or consent of the Holders of at least a majority of the then outstanding shares of the Series G Preferred Stock represented at a duly held meeting at which a quorum is present or by written consent of Holders of a majority of the outstanding Series G Preferred Stock (except as otherwise may be required under the DGCL) shall constitute the approval of such action by the class or series. To the extent that under the DGCL holders of the Series G Preferred Stock are entitled to vote on a matter with holders of Common Stock, voting together as one class, each share of Series G Preferred Stock shall be entitled to a number of votes as provided in the paragraph above using the record date for the taking of such vote of stockholders as the date as of which the Conversion Price is calculated.

Section 5. Liquidation . Upon any liquidation, dissolution or winding-up of the Corporation, whether voluntary or involuntary (a “ Liquidation ”), no distribution shall be made to the holders of any shares of capital stock of the Corporation unless, prior thereto, the Holders shall have received out of the available assets, whether capital or surplus, of the Corporation an amount equal to 100% of the Stated Value, plus any accrued and unpaid dividends thereon and any other fees or liquidated damages owing thereon, for each share of Series G Preferred Stock. If the assets of the Corporation shall be insufficient to pay in full such amounts due the Holders, then the entire assets shall be distributed ratably among the Holders in accordance with the respective amounts that would be payable on such shares if all amounts payable thereon were paid in full. A Fundamental Transaction, as defined in Section 7(b) below, or a Change of Control Transaction, as defined above, shall be deemed to be a Liquidation. The Corporation shall mail written notice of any such Liquidation, not less than 30 calendar days prior to the payment date stated therein, to each Holder.

Section 6. Conversion .

(a) Voluntary Conversions at Option of Holder . Each share of Series G Preferred Stock shall be convertible commencing 60 calendar days after the date on which the last share of Series G Preferred Stock is issued pursuant to a Purchase Agreement, at the option of the Holder, into that number of shares of Common Stock determined by dividing the Stated Value of such share of Series G Preferred Stock by the Conversion Price. Holders shall effect conversions by providing the Corporation with the form of conversion notice attached hereto as Annex A (a “ Notice of Conversion ”). Holders may effect a voluntary conversion for all or a portion of the Series G Preferred Shares held by such Holder. Each Notice of Conversion shall specify the number of shares of Series G Preferred Stock to be converted and the date on which such conversion is to be effected, which date may not be prior to the date the applicable Holder delivers by facsimile such Notice of Conversion to the Corporation (such date, the “ Conversion Date ”). If no Conversion Date is specified in a Notice of Conversion, the Conversion Date shall be the date that such Notice of Conversion to the Corporation is deemed delivered hereunder. The calculations and entries set forth in the Notice of Conversion shall control in the absence of manifest or mathematical error. In the case of any dispute with respect to a conversion, the Corporation shall promptly issue such number of shares of Common Stock as are not disputed in accordance with the Notice of Conversion. If such dispute involves the calculation of the Conversion Price, and such dispute is not promptly resolved by discussion between the relevant Holder and the Corporation, the Corporation shall submit the disputed calculations to an independent outside accountant via facsimile or email within three Business Days of receipt of the Notice of Conversion. The accountant, at the Corporation’s sole expense, shall promptly review the calculations and notify the Corporation and the Holder of the results no later than three Business Days from the date it receives the disputed calculations. The accountant’s calculation shall be deemed conclusive, absent manifest error. Each holder shall surrender or cause to be surrendered the original certificates representing shares of the Series G Preferred Stock to effect a voluntary conversion, in whole or in part, of such shares, and, if only a portion of the shares of Series G Preferred Stock held by such Holder are being converted, the Corporation will issue a new certificate indicating the shares of Series G Preferred Stock still held by the Holder following the partial conversion. Shares of Series G Preferred Stock converted into Common Stock or redeemed by conversion as described below in accordance with the terms hereof shall be canceled and shall not be reissued. Notwithstanding the foregoing, no voluntary conversion may be effected at any time when the Corporation does not have adequate authorized, unissued shares of Common Stock to effect the conversion of all Series G Preferred Stock or if the then-applicable Conversion Price is less than the par value of the Common Stock to be issued upon conversion.

(b) Conversion Price . The initial conversion price for the Series G Preferred Stock shall be equal to $0.0033 (the “ Initial Conversion Price ”), subject to any adjustments pursuant to Section 7 below. As long as any of the Series G Preferred Stock is outstanding, the conversion price of the Series G Preferred Stock shall be adjusted pursuant to Section 7 (such price, as adjusted, the “ Adjusted Conversion Price ” and such price or the Initial Conversion Price, as applicable at any measurement time, the “ Conversion Price ”).

(c) Mandatory Conversion . Upon either (i) a Qualified Public Offering or (ii) the affirmative vote of the Holders of a simple majority of the Stated Value of the Series G Preferred Stock issued and outstanding, all outstanding shares of Series G Preferred Stock, plus all accrued or declared, but unpaid, dividends thereon, shall mandatorily be converted into such number of shares of Common Stock determined by dividing the Stated Value of such Series G Preferred Stock (together with the amount of any accrued or declared, but unpaid, dividends thereon) by the Conversion Price then in effect. No fractional shares of Common Stock shall be issued upon the conversion of any share of Series G Preferred Stock; the number of shares of Common Stock to be issued shall be rounded to the nearest whole number. All outstanding Series G Preferred Stock shall convert upon a Mandatory Conversion.

(d) Mandatory Redemption . If not earlier converted, the Series G Preferred Stock shall be redeemed by conversion on the Mandatory Redemption Date at the then applicable Conversion Price. The Series G Preferred Stock shall not be redeemed by payment of cash or property, or shall have any claim to cash or property at any time or under any circumstances (except pursuant to Liquidation consistent with Section 5 above) but only by conversion into Common Stock.

(e) Mechanics of Conversion or Redemption

(i) Delivery of Certificate Upon Conversion or Redemption . Not later than five Trading Days after each Conversion Date (the “ Share Delivery Date ”), the Corporation shall deliver, or cause to be delivered, to the converting Holder a certificate or certificates representing the number of Conversion Shares being acquired upon the conversion of shares of Series G Preferred Stock. If in the case of any Notice of Conversion such certificate or certificates are not delivered to or as directed by the applicable Holder by the third Trading Day after the Conversion Date, the applicable Holder shall be entitled to elect to rescind such Conversion Notice by written notice to the Corporation at any time on or before its receipt of such certificate or certificates, in which event the Corporation shall promptly return to such Holder any original Series G Preferred Stock certificate delivered to the Corporation and such Holder shall promptly return to the Corporation any Common Stock certificates representing the shares of Series G Preferred Stock unsuccessfully tendered for conversion to the Corporation.

(ii) Obligation Absolute . The Corporation’s obligation to issue and deliver the Conversion Shares upon conversion of Series G Preferred Stock in accordance with the terms hereof are irrespective of any action or inaction by a Holder to enforce the same, any waiver or consent with respect to any provision hereof, the recovery of any judgment against any Person or any action to enforce the same, or any setoff, counterclaim, recoupment, limitation or termination, or any breach or alleged breach by such Holder or any other Person of any obligation to the Corporation or any violation or alleged violation of law by such Holder or any other Person, and irrespective of any other circumstance which might otherwise limit such obligation of the Corporation to such Holder in connection with the issuance of such Conversion Shares; provided , however , that such delivery shall not (i) be required if such delivery would be a violation of law, and (ii) operate as a waiver by the Corporation of any such action that the Corporation may have against such Holder.

(iii) Reservation of Shares Issuable Upon Conversion . If at the time of the issuance of the Series G Preferred Stock, the Corporation does not have an adequate number of authorized shares of Common Stock available for issuance upon conversion of the Series G Preferred Stock, the Corporation shall, as soon as practicable, take such corporate action as may be necessary to increase its authorized but unissued shares of Common Stock to such number of shares as shall be sufficient for such purposes, including, without limitation, engaging in good faith, commercially reasonable efforts to obtain the requisite stockholder approval of any necessary amendment to the Certificate of Incorporation. Thereafter, the Corporation shall take all necessary corporate action (including, without limitation, calling shareholders’ meetings for the purpose of voting to increase the number of available authorized shares) to ensure that at all times it has reserved and kept available out of its authorized and unissued shares of Common Stock for the sole purpose of issuance upon conversion of the Series G Preferred Stock, free from preemptive rights or any other actual contingent purchase rights of Persons other than the Holders of the Series G Preferred Stock, not less than such aggregate number of shares of the Common Stock as shall (subject to the terms and conditions in the Purchase Agreement(s)) be issuable (taking into account the adjustments provided for in Section 7 ) upon the conversion of all outstanding shares of Series G Preferred Stock, as well as all other shares of Common Stock issuable upon conversion or exercise of any other issued and outstanding securities. Such shares of issuable Common Stock shall, upon issue, be duly authorized, validly issued, fully paid and non-assessable.

(iv) Maintaining appropriate par value . If at the time of the issuance of the Series G Preferred Stock, the Conversion Price of the Common Stock to be issued upon conversion of the Series G Preferred Stock would be below the par value of such Common Stock, the Corporation shall, as soon as practicable, take such corporate action as may be necessary to adjust the par value of Common Stock, including, without limitation, engaging in good faith, commercially reasonable efforts to obtain the requisite stockholder approval of any necessary amendment to the Certificate of Incorporation. Thereafter, the Corporation shall take all necessary corporate action (including, without limitation, calling shareholders’ meetings) to ensure that at all times it has maintained the par value of the Common Stock so that such shares of Common Stock shall, upon issue, be duly authorized, validly issued, fully paid and non-assessable.

(v) Transfer Taxes . The issuance of certificates for shares of Common Stock upon conversion of Series G Preferred Stock shall be made without charge to any Holder for any documentary stamp or similar taxes that may be payable in respect of the issue or delivery of such certificates, provided that (a) the Corporation shall not be required to pay any tax that may be payable in respect of any transfer involved in the issuance and delivery of any such certificate upon conversion in a name other than that of the Holders of such shares and (b) the Corporation shall not be required to issue or deliver such certificates unless or until the Person or Persons requesting the issuance thereof shall have paid to the Corporation the amount of such tax or shall have established to the satisfaction of the Corporation that such tax has been paid.

Section 7. Certain Adjustments .

(a) Stock Dividends and Stock Splits . If the Corporation, while any Series G Preferred Stock is outstanding: (A) pays a permissible stock dividend or otherwise makes a permissible distribution or distributions payable in shares of Common Stock on shares of Common Stock or any other Common Stock Equivalents (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Corporation upon conversion or redemption of the Series G Preferred Stock, including any accrued or declared, but unpaid, dividends thereon; (B) subdivides outstanding shares of Common Stock into a larger number of shares; (C) combines (including by way of a reverse stock split) outstanding shares of Common Stock into a smaller number of shares; or (D) issues, in the event of a reclassification of shares of Common Stock, any shares of capital stock of the Corporation, then the Conversion Price shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock on a fully converted and exercised basis (excluding any treasury shares of the Corporation) outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event. Any adjustment made pursuant to this Section 7(a) shall become effective immediately after (i) the record date for the determination of stockholders entitled to receive such dividend or distribution or (ii) the effective date in the case of a subdivision, combination or reclassification.

(b) Fundamental Transaction . If, at any time while the Series G Preferred Stock is outstanding, the Corporation effects (A) any merger or consolidation of the Corporation with or into another person, (B) any sale of all or substantially all of its assets in one transaction or a series of related transactions, (C) any tender offer or exchange offer (or a third party effects such a tender offer or exchange offer) pursuant to which holders of Common Stock are permitted to tender or exchange their shares for other securities, cash or property, or (D) any reclassification of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property (in any such case, a “ Fundamental Transaction ”), then, upon any subsequent conversion of this Series G Preferred Stock, the Holders shall have the right to receive, for each Conversion Share that would have been issuable upon such conversion immediately prior to the occurrence of such Fundamental Transaction, the same kind and amount of securities, cash or property as it would have been entitled to receive upon the occurrence of such Fundamental Transaction if it converted the Series G Preferred Stock prior to the Fundamental Transaction. For purposes of any such conversion, the determination of the Conversion Price shall be appropriately adjusted as if such conversion occurred immediately prior to such Fundamental Transaction. If holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction (“ Alternate Consideration ”), then the Holders shall be given the same choice as to the Alternate Consideration as the Holders shall receive upon any conversion of this Series G Preferred Stock following such Fundamental Transaction. The Corporation shall cause any successor entity in a Fundamental Transaction in which the Corporation is not the survivor (the “ Successor Entity ”) to assume in writing all of the obligations of the Corporation under this Certificate of Designations in accordance with the provisions of this Section 7(b) pursuant to written agreements in form and substance reasonably satisfactory to Holders of a majority of the then outstanding Series G Preferred Stock and approved by such Holders prior to such Fundamental Transaction and shall, at the option of each Holder, deliver to such Holder, in exchange for the shares of Series G Preferred Stock, a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to the certificates representing the shares of Series G Preferred Stock which is exercisable for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) or other consideration equivalent to the shares of Common Stock acquirable and receivable upon exercise of the Series G Preferred Stock prior to such Fundamental Transaction, and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction, the provisions of this Certificate of Designations and the other Transaction Documents referring to the “Corporation” shall refer instead to the Successor Entity), and may exercise every right and power of the Corporation and shall assume all of the obligations of, the Corporation under this Certificate of Designations and the Purchase Agreement with the same effect as if such Successor Entity had been named as the Corporation herein and therein.

(c) Calculations . All calculations under this Section 7 shall be made to the nearest 1/1000th of a share, as the case may be. For purposes of this Section 7 , the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall exclude any treasury shares of the Corporation.

(d) Notice to the Holders .

(i) Adjustment to Conversion Price . Whenever the Conversion Price is adjusted pursuant to any provision of this Section 7 , the Corporation shall promptly deliver to each Holder a notice setting forth the then current Conversion Price after such adjustment and setting forth a brief statement of the facts requiring such adjustment.

(ii) Notice to Holders . If (A) the Corporation shall declare a permissible dividend (or any other permissible distribution in whatever form) on the Common Stock, (B) the Corporation shall declare a permissible special nonrecurring cash dividend on or a permissible redemption of the Common Stock, (C) the Corporation shall authorize the permissible granting to all holders of the Common Stock of rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights, (D) the approval of any stockholders of the Corporation shall be required in connection with any reclassification of the Common Stock, any consolidation or merger to which the Corporation is a party, any sale or transfer of all or substantially all of the assets of the Corporation, of any compulsory share exchange whereby the Common Stock is converted into other securities, cash or property or (E) the Corporation shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Corporation, then, in each case, the Corporation shall cause to be delivered to each Holder at its last address as it shall appear upon the stock books of the Corporation, at least 20 calendar days prior to the applicable record or effective date with respect to such action or event, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are otherwise to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other property deliverable upon such distribution (which may include a dividend), reclassification, consolidation, merger, sale, transfer or share exchange, provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to be specified in such notice.

Section 8. Protective Provisions .

So long as any shares of Series G Preferred Stock are outstanding, the Corporation shall not take any of the following corporate actions (whether by merger, consolidation or otherwise) without first obtaining the approval (by vote or written consent, as provided by the DGCL) of the Holders of a majority of the then outstanding shares of Series G Preferred Stock:

(a) alter or change adversely the rights, preferences, powers or privileges of the Series G Preferred Stock, alter or amend this Certificate of Designation, or increase the authorized number of shares of Series G Preferred Stock;

(b) alter or change the rights, preferences or privileges of any capital stock of the Corporation so as to affect adversely the Series G Preferred Stock;

(c) redeem, repurchase or otherwise acquire, or declare or pay any cash dividend or distribution on, any Junior Securities;

(d) increase the par value of the Common Stock;

(e) enter into any agreement, commitment, understanding or other arrangement to take any of the foregoing actions; or

(f) cause or authorize any Subsidiary to engage in any of the foregoing actions.

Notwithstanding the foregoing, no change pursuant to this Section 8 shall be effective to the extent that, by its terms, it applies to less than all of the Holders of shares of Series G Preferred Stock then outstanding.

Section 9. Miscellaneous.

(a) Notices . Any and all notices or other communications or deliveries to be provided by the Holders hereunder including, without limitation, any Notice of Conversion, shall be in writing and delivered personally, by facsimile, or sent by a nationally recognized overnight courier service, addressed to the Corporation, at the address set forth in the Corporation’s filings with the Commission or to the facsimile number provided in the Corporation’s filings with the Commission , or such other facsimile number or address as the Corporation may specify for such purposes by notice to the Holders delivered in accordance with this Section 9 . Any and all notices or other communications or deliveries to be provided by the Corporation hereunder shall be in writing and delivered personally, by facsimile, or sent by a nationally recognized overnight courier service addressed to each Holder at the facsimile number or address of such Holder appearing on the signature page of the Purchase Agreement, or such other address as may be designated by such Holder in accordance with this Section 9(a) . Any notice or other communication or deliveries hereunder shall be deemed given and effective on the earliest of (i) the date of transmission, if such notice or communication is delivered via facsimile at the facsimile number specified in this Section 9 prior to 5:30 p.m. (New York City time) on any date, (ii) the date immediately following the date of transmission, if such notice or communication is delivered via facsimile at the facsimile number specified in this Section 9 between 5:30 p.m. and 11:59 p.m. (New York City time) on any date, (iii) the second Business Day following the date of mailing, if sent by nationally recognized overnight courier service, or (iv) upon actual receipt by the party to whom such notice is required to be given.

(b) Lost or Mutilated Series G Preferred Stock Certificate . If a Holder’s Series G Preferred Stock certificate shall be mutilated, lost, stolen or destroyed, the Corporation shall execute and deliver, in exchange and substitution for and upon cancellation of a mutilated certificate, or in lieu of or in substitution for a lost, stolen or destroyed certificate, a new certificate for the shares of Series G Preferred Stock so mutilated, lost, stolen or destroyed, but only upon receipt of evidence of such loss, theft or destruction of such certificate, and of the ownership hereof reasonably satisfactory to the Corporation. However, the Corporation shall not be obligated to reissue such mutilated, lost, stolen or destroyed Series G Preferred Stock certificate if the Holder contemporaneously requests the Corporation to convert such Preferred Stock

(c) Governing Law . All questions concerning the construction, validity, enforcement and interpretation of this Certificate of Designation shall be governed by and construed and enforced in accordance with the internal laws of the State of Delaware, without regard to the principles of conflict of laws of that or any other jurisdiction. Each party agrees that all legal proceedings concerning the interpretation, enforcement and defense of the transactions contemplated by this Certificate of Designation or the Purchase Agreement and any related schedule, exhibit, annex or other document (whether brought against a party hereto or its respective Affiliates, directors, officers, shareholders, employees or agents) shall be commenced in the state and federal courts sitting in the City of Wilmington, State of Delaware (the “ Delaware Courts ”). Each party hereto hereby irrevocably submits to the exclusive jurisdiction of the Delaware Courts for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein (including with respect to the enforcement of any of the Transaction Documents), and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of such Delaware Courts, or such Delaware Courts are improper or inconvenient venue for such proceeding. Each party hereto hereby irrevocably waives, to the fullest extent permitted by applicable law, any and all right to trial by jury in any legal proceeding arising out of or relating to this Certificate of Designation or the transactions contemplated hereby.

(d) Waiver . Any waiver by the Corporation or a Holder of a breach of any provision of this Certificate of Designation shall not operate as or be construed to be a waiver of any other breach of such provision or of any breach of any other provision of this Certificate of Designation or a waiver by any other Holder. The failure of the Corporation or a Holder to insist upon strict adherence to any term of this Certificate of Designation on one or more occasions shall not be considered a waiver or deprive that party (or any other Holder) of the right thereafter to insist upon strict adherence to that term or any other term of this Certificate of Designation. Any waiver by the Corporation or a Holder must be in writing.

(e) Severability . If any provision of this Certificate of Designation is determined to be invalid, illegal or unenforceable, the balance of this Certificate of Designation shall remain in effect, and if any provision is inapplicable to any Person or circumstance, it shall nevertheless remain applicable to all other Persons and circumstances. If it shall be found that any dividend, interest or other amount deemed interest due hereunder violates the applicable law governing usury, the applicable rate of such dividend or interest due hereunder shall automatically be lowered to equal the maximum rate of interest permitted under applicable law.

(f) Next Business Day . Whenever any payment or other obligation hereunder shall be due on a calendar day other than a Business Day, such payment shall be made on the next succeeding Business Day.

(g) Headings . The headings contained herein are for convenience only, do not constitute a part of this Certificate of Designation and shall not be deemed to limit or affect any of the provisions hereof.

(h) Status of Converted or Redeemed Series G Preferred Stock . Shares of Series G Preferred Stock may only be issued pursuant to the Purchase Agreement and any related document. If any shares of Series G Preferred Stock shall be converted, redeemed or reacquired by the Corporation, such shares shall resume the status of authorized but unissued shares of preferred stock and shall no longer be designated as Series G 1.5% Convertible Preferred Stock.

*********************

IN WITNESS WHEREOF, the undersigned has executed this Certificate of Designation of Preferences, Rights and Limitations of the Series G 1.5% Convertible Preferred Stock this ___ day of __________ 2014.

	CORTEX PHARMACEUTICALS, INC.


	Name: Arnold S. Lippa
	Title: Chief Executive Officer

ANNEX A

NOTICE OF CONVERSION

(To be Executed by the Registered Holder in order to Convert Shares of SERIES G Preferred Stock)

The undersigned hereby elects to convert the number of shares of Series G 1.5% Convertible Preferred Stock indicated below into shares of common stock, par value $0.001 per share (the “ Common Stock ”), of Cortex Pharmaceuticals, Inc., a Delaware corporation (the “ Corporation ”), according to the conditions hereof, as of the date written below. If shares of Common Stock are to be issued in the name of a Person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto and is delivering herewith such certificates and opinions as may be required by the Corporation in accordance with the applicable Purchase Agreement. No fee will be charged to the Holders for any conversion, except for any such transfer taxes.

Conversion calculations:

Date to Effect Conversion:

Number of shares of Series G Preferred Stock to be Converted:

Stated Value of shares of Series G Preferred Stock to be Converted:

Number of shares of Common Stock to be Issued:

Conversion Price:

Address for Delivery:

DWAC Instructions:

Broker no:
Account no:

[HOLDER]

By:
	Name:
	Title:

Exhibit 10.1

SECURITIES PURCHASE AGREEMENT

This SECURITIES PURCHASE AGREEMENT (the “ Agreement ”), dated as of [______ ___], 2014, is made by and among Cortex Pharmaceuticals, Inc., a corporation organized under the laws of the State of Delaware (the “ Company ”), and each of the purchasers (individually, a “ Purchaser ” and collectively the “ Purchasers ”), as set forth on the execution pages hereof (each, an “ Execution Page ” and collectively, the “ Execution Pages ”). This document may be executed in multiple counterparts with multiple Execution Pages. Collectively and individually, these multiple counterparts shall be considered part of one original document.

BACKGROUND

A. The Company and each Purchaser are executing and delivering this Agreement in reliance upon the exemption from securities registration afforded by the provisions of Regulation D (“ Regulation D ”), as promulgated by the United States Securities and Exchange Commission (the “ SEC ”) under the Securities Act of 1933, as amended (the “ Securities Act ”).

B. Upon the terms and conditions stated in this Agreement, the Company desires to issue and sell to the Purchasers, and each Purchaser desires to purchase shares of the Company’s Series G 1.5% Convertible Preferred Stock, par value $0.001 per share (the “ Series G Preferred Stock ”), which Series G Preferred Stock shall have the rights, preferences and privileges as set forth in the form of Certificate of Designation, Preferences and Rights attached hereto as Exhibit A (the “ Certificate of Designation ”), and which shares of Series G Preferred Stock (with a stated value of $1,000 per share) shall initially be convertible into shares of the Company’s common stock, par value $0.001 per share (the “ Common Stock ”) at the initial conversion rate of $0.0033 per share of Common Stock (the “ Offering ”). For avoidance of doubt, the number of shares of Common Stock to be issued upon conversion shall be (i) the amount of stated value of the shares of Series G Preferred Stock to be converted (ii) divided by the conversion rate. The shares of Common Stock issuable upon conversion or redemption or otherwise pursuant to the Series G Preferred Stock are referred to herein as the “ Conversion Shares .” The Series G Preferred Stock and the Conversion Shares are collectively referenced herein as the “ Securities ” and each of them may individually be referred to herein as a “ Security .”

NOW, THEREFORE, in consideration of the premises and mutual covenants contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Company and the Purchasers, intending to be legally bound, hereby agree as follows:

1. PURCHASE AND SALE OF SECURITIES.

(a) Purchase and Sale of Securities . Subject to the terms and conditions hereof, at the Closing (as defined in Section 1(c) below), the Company shall issue and sell to each Purchaser, and each Purchaser, severally and not jointly, shall purchase from the Company, such number of shares of Series G Preferred Stock as is set forth on such Purchaser’s Execution Page, for a purchase price (as to each Purchaser, the “ Purchase Price ”) per share equal to One Thousand Dollars ($1,000). The Closing is subject to the Company’s receipt of subscriptions for the Securities aggregating at least $750,000 (the “ Minimum ”); provided that, of the Minimum , not more than $350,000 in the aggregate may be provided by: (i) current officers and directors of the Company (or their affiliates), and (ii) any stockholder that individually (together with its affiliates) holds beneficially and/or of record 10% or more of the outstanding capital stock of the Company. Certain affiliates of the Company may lend up to $150,000 on a secured basis to the Company prior to the first Closing, which loans shall be converted at Closing into Series G Preferred Stock, and the amounts contributed pursuant to such converted loans may be utilized in whole or part to satisfy the minimum amount.

(b) Voting Agreement . Each Purchaser hereby agrees that, as a condition to Closing, such Purchaser shall execute and deliver the form of Written Consent of Stockholders attached hereto as Exhibit B , which Written Consent of Stockholders is necessary in order to effectuate the amendment to the Company’s Certificate of Incorporation (“ Charter Amendment ”) substantially in the form attached hereto as Exhibit C , which Charter Amendment will increase the number of authorized shares of Common Stock that the Company may issue from 205,000,000 shares of Common Stock to 1,400,000,000 shares of Common Stock. The Written Consent of Stockholders shall also authorize the Cortex Pharmaceuticals, Inc. 2014 Equity, Equity-Linked and Equity Derivative Incentive Plan covering the issuance of restricted shares or options for up to 105,633,002 shares of Common Stock or options therefore.

(c) The Closing . The initial and subsequent closings of the transactions contemplated hereby (each, a “ Closing ”) shall take place at the offices of Drinker Biddle & Reath LLP at One Logan Square, 18th & Cherry Streets, Philadelphia, Pennsylvania 19103 at 10:00 a.m., Philadelphia, Pennsylvania time, on the date upon which the minimum of $750,000 has been raised as provided for in Section 1(a) above or after such date, from time-to-time, or such other times or places as the Company and the Purchasers may mutually agree (each, a “ Closing Date ”).

2. RISK FACTORS.

AN INVESTMENT IN THE SECURITIES INVOLVES A HIGH DEGREE OF RISK AND SHOULD ONLY BE CONSIDERED BY THOSE PERSONS WHO CAN AFFORD THE LOSS OF THEIR ENTIRE INVESTMENT. PROSPECTIVE PURCHASERS SHOULD CAREFULLY CONSIDER THE FOLLOWING RISK FACTORS, AND THE OTHER INFORMATION SET FORTH IN THIS AGREEMENT (AND THE EXHIBITS HERETO), IN CONNECTION WITH AN INVESTMENT IN THE SECURITIES. THE FOLLOWING RISK FACTORS ARE SUMMARIES AND ARE NOT INTENDED TO BE EXHAUSTIVE OR TO SET FORTH ALL POSSIBLE RISKS AND UNCERTAINTIES INVOLVED. THE ORDER IN WHICH THE RISK FACTORS APPEAR IS NOT INTENDED AS AN INDICATION OF THE RELATIVE WEIGHT OR IMPORTANCE THEREOF. EACH PROSPECTIVE INVESTOR IS STRONGLY ENCOURAGED TO CONSULT WITH PROFESSIONAL FINANCIAL ADVISORS, ACCOUNTANTS AND/OR LAWYERS IN DECIDING WHETHER TO INVEST IN THE SECURITIES. THERE MAY BE ADDITIONAL RISKS OF WHICH WE ARE NOT PRESENTLY AWARE OR WHICH WE CURRENTLY VIEW AS NOT SIGNIFICANT OR MATERIAL, WHICH MAY IN THE FUTURE BECOME SIGNIFICANT OR MATERIAL.

WHEN WORDS SUCH AS “WE” AND “OUR” AND/OR WORDS OF SIMILAR IMPORT ARE USED IN THE RISK FACTORS SUCH WORDS REFER TO THE COMPANY.

(a) Risks Related to Us and Our Business.

The Company in currently not current in it public reporting requirements with the SEC.

The Company has not filed its Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2012. The Company has not filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2012, which would include its audited financial statements as of and for the year ended December 31, 2012. The Company has not filed its Quarterly Report on Form 10-Q for the quarterly periods ended March 31, 2013, June 30, 2013 and September 30, 2013. Although the Company has begun the process to bring its financial filings current, such filings are not expected to be current until April 2014. Any financial information presented herein for such periods is necessarily estimated and is not audited. There is very limited current financial information available about the Company and the currently available information may not be accurate. There can be no assurances as to when the Company may become current in its SEC filing requirements, if ever. In a letter dated November 7, 2013 from the SEC, the SEC informed the Company that it believed that the Company was not current in its required filings and that if not current, the Company should file the required reports within fifteen (15) days of the date of the letter. The SEC warned that the Company may be the subject of an administrative proceeding to revoke its registration under the Securities Exchange Act of 1934. Furthermore, trading in the Company’s stock may be suspended until the Company is current in its filings, or longer. The Company has been in contact with the SEC and has presented its intended schedule to bring its filings current. The Company intends to meet these milestones; however, there can be no assurances regarding what, if any, actions the SEC will choose to take and when it may take them.

Our independent registered public accounting firm has expressed substantial doubt about our ability to continue as a going concern.

In its audit opinion issued in connection with our balance sheets as of December 31, 2011 and 2010 and our statements of operations, stockholder’s equity and comprehensive income (loss), and cash flows for the years ended December 31, 2011 and 2010, our independent registered public accounting firm has expressed substantial doubt about our ability to continue as a going concern given our limited working capital, recurring net losses and negative cash flows from operations. There has not been a subsequent audit of the Company since those audit opinions were issued. The financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts of liabilities that might be necessary should we be unable to continue in existence. While we have relied principally in the past on external financing to provide liquidity and capital resources for our operations, we can provide no assurances that cash generated from our operations together with cash received in the future from external financing (including this Offering) will be sufficient to enable us to continue as a going concern.

We have a history of net losses; we expect to continue to incur net losses and we may never achieve or maintain profitability.

Since our formation on February 10, 1987 through the end of our most recent reported fiscal year ended December 31, 2011, we have generated only modest operating revenues and we have incurred net losses of $120,769,087 (audited). Since formation through June 30, 2012, our accumulated deficit, which reflects our accumulated net losses, was $122,697,864 (unaudited). For the fiscal year ended December 31, 2011, our net loss was $2,254,847 (audited). For the six months ended June 30, 2012, our net loss was $1,928,777 (unaudited). We have not generated any revenue from product sales to date, and it is possible that we will never generate revenues from product sales in the future. Even if we do achieve significant revenues from product sales, we expect to incur significant operating losses over the next several years. As with other companies in the biotechnology industry, it is possible that we will never achieve profitable operations.

We will need additional capital in the future and, if such capital is not available on terms acceptable to us or available to us at all, we may need to scale back our research and development efforts and may be unable to continue our business operations.

The Company does not expect to be able to pay its liabilities and fund its business activities going forward without raising additional capital. As a result of the Company’s current financial situation, the Company believes that is has very limited access to external sources of debt and equity financing. Accordingly, there can be no assurances that the Company will be able to secure the additional financing required to fund its operating and debt service requirements. If the Company is unable to access sufficient cash resources, the Company may be forced to discontinue its operations entirely and liquidate.

The Company is currently, and has been for some time, under significant financial distress. It has limited cash resources and current assets, and has no ongoing source of revenue. Since late 2012, the Company’s business activities have been reduced to minimal levels, and the prior management of the Company, which was removed on March 22, 2013, had retained bankruptcy counsel to assist it in considering whether to file for Chapter 7 liquidation. New management, appointed during March and April 2013, is currently in the process of evaluating the status of numerous aspects of the Company’s existing business and obligations (which in some cases involves the renegotiation of certain matters), including, without limitation, accounts payable and accrued expenses, debt obligations, financial requirements, intellectual property, licensing agreements, legal and patent matters and regulatory compliance. The Company’s ability to conduct and finance its operations is dependent upon the success of efforts by new management, which success cannot be assured. Our Chief Executive Office, Arnold S. Lippa, devotes his full time professional efforts to the Company. Other directors and officers of the Company have business commitments and obligations other than with the Company and therefore do not currently devote their full time efforts to the Company; however, these directors and officers intend to devote as much support as is needed.

We will require substantial additional funds to continue our operations and to advance our research and development programs, particularly if we decide to independently conduct later-stage clinical testing and apply for regulatory approval of any of our proposed products. Additionally, we may require additional funds in the event that we decide to pursue strategic acquisitions of or licenses for other products or businesses. Based on our current operating plans, we estimate that our existing cash resources will be sufficient to meet our working capital requirements through approximately May 31, 2014, assuming that we fund the minimum amount of the Offering, and through approximately November 30, 2014, assuming that we fund the maximum amount of the Offering. We believe that we will require additional capital in 2014 to fund on-going operations in addition to the funds from the current offering. Additional funds may result from agreements with larger pharmaceutical or biopharmaceutical companies that include the license or rights to the technologies and products that we are currently developing, although there is no assurance that we will secure such a transaction in a timely manner, or on terms acceptable to us or at all. As of July 31, 2013, warrants to purchase up to 4,000,000 shares of our Common Stock were outstanding, exercisable at $0.056 per share. As of February 17, 2014, there were 10,538,647 options outstanding, with exercise prices ranging from $0.06 to $2.95 per share. On August 10, 2012, an additional 5,166,668 options exercisable at $0.06 and expiring in ten years were issued as severance options to two executives; these options were fully vested upon issuance. In addition, the Company expects to issue an additional 4,300,000 options to four former executives as part of a settlement of monetary claims by such executives totaling approximately $1.3 million, exercisable at the closing stock price of the Company’s Common Stock the day before the closing and exercisable for five years or ten years. In addition, approximately $140,000 will be paid to such former executives from the net proceeds of this Offering and the former executives and the Company are releasing one another. The Company may issue additional warrants and options in the future and may do so as a means to settle certain liabilities. There can be no assurance that such warrants and options will ever be exercised, and as such may not provide any additional funds to the Company. The Company intends to issue restricted stock to certain officers, directors, consultants and advisors in exchange for services rendered or to be rendered, but the Company will not be receiving any additional funds upon such issuance.

Our cash requirements in the future may differ significantly from our current estimates, depending on a number of factors, including, but not limited to:

1. the results of our clinical trials;

2. the time and costs involved in obtaining regulatory approvals;

3. the ability to obtain funding under contractual and licensing agreements;

4. the costs involved in obtaining and enforcing patents or any litigation by third parties regarding intellectual property;

5. our success in entering into collaborative relationships with other parties; and

6. the time and costs involved in bringing the Company’s filings current with the Securities and Exchange Commission.

To finance our future activities, we may seek funds through additional rounds of financing, including private or public equity or debt offerings and collaborative arrangements with corporate partners. We cannot say with any certainty that we will be able to obtain the additional needed funds on reasonable terms, or at all. The sale of additional equity or convertible debt securities could result in additional dilution to our stockholders. If we issued additional preferred equity or debt securities, these securities could have rights superior to holders of our Common Stock and the Series G Preferred Stock, and such instruments entered into in connection with the issuance of securities could contain covenants that will restrict our operations. We might have to obtain funds through arrangements with collaborative partners or others that may require us to relinquish rights to our technologies, product candidates or products that we otherwise would not relinquish. In addition, we may be unable to meet our research spending obligations under our existing licensing agreements and may be unable to continue our business operations.

Our products rely on licenses from research institutions and if we lose access to these technologies or the related patent applications, our business would be substantially impaired.

Our rights to certain of the early AMPAKINE compounds were the subject of license agreements involving patents or patent applications owned wholly by The Regents of the University of California or by the University as a co-owner with us. The agreements with The Regents of the University of California have been cancelled. The Company believes that the related patents would have expired before any commercialization opportunity. The Company does not believe this license agreement is material or necessary for its current drug development plans. However, the Company may not necessarily be correct in its belief. The license fees owed by the Company under the agreement were not paid and the license was terminated on April 15, 2013. The Company is currently in discussions with the University of California regarding the amount of the fees owed by the Company under the license agreement and a possible settlement of that amount. There can be no assurances that a settlement in an amount less than the total amount owed will be reached. If the total amount owed must be paid, it would have an adverse impact on the Company.

Under a patent license agreement with The Governors of the University of Alberta, we acquired exclusive rights to the use of AMPAKINE compounds to prevent and treat respiratory depression induced by opiate analgesics, barbiturates and anesthetic and sedative agents. In connection with our transaction with Biovail, we assigned our rights under our patent license agreement with the University of Alberta to Biovail. However, we retained our ability to continue to pursue AMPAKINE compounds as a potential treatment for sleep apnea disorders. As part of our agreement to reacquire our assets from Biovail in March 2011, the rights assigned to Biovail under our patent license agreement with the University of Alberta were returned to us. However, BioVail retains certain economic rights to the intravenous use of some of the compounds that were the subject of the BioVail agreement. Unless the terms can be renegotiated, of which there can be no assurance, these rights may have an adverse impact on the economics of developing intravenous formulations with respect to the compounds.

On March 22, 2013, the Company received a letter from the University of Illinois indicating that the license agreement entered into on October 10, 2007 between the University of Illinois and Pier Pharmaceuticals, Inc., a wholly-owned subsidiary of the Company (as amended, the “License Agreement”), had been terminated on March 21, 2013. Pier Pharmaceuticals Inc., known as SteadySleep RX Co. at the time the License Agreement was entered into, was acquired by the Company in a merger effective August 10, 2012. On February 19, 2013, the University of Illinois had notified the Company of a default under the License Agreement due to non-payment of a $75,000 milestone fee due December 31, 2012. Under the terms of the License Agreement, the Company had 30 days to cure the default, which it did not do. On the same date as the receipt of the termination letter, newly appointed officers of the Company initiated discussions with the University of Illinois regarding the possibility of extending the cure period or otherwise amending the License Agreement. On April 1, 2013, after considering the Company’s proposals, the University of Illinois informed the Company that, while it believed the License Agreement was terminated, it remained open to negotiating a new license agreement. Accordingly, the Company and the University of Illinois currently are in discussions regarding the terms of a new license. There can be no assurances that a new license will be agreed upon. Regardless of whether such new license agreement is reached, due to its rights of inventorship and independent of the License Agreement, the Company remains free to practice additional patents and patent applications describing a dosage range for the use of dronabinol in the treatment of sleep apnea, as well as for various formulations of dronabinol. There can be no assurances that the University of Illinois will not pursue other license partners given their rights of inventorship claim in respect to the same patent. If the University of Illinois were to enter into a new license with a different party or develop the intellectual property on its own, the Company would face direct competition, which could be materially adverse to the Company.

We are subject to certain payment obligations under our license agreements, some of which we are in the process of renegotiating or settling; failure to successfully negotiate these amounts may adversely affect our business.

As described above, we are in negotiations regarding several of our licenses including with respect to the terms of certain licenses going forward and fees owed under certain existing licenses. If we cannot resolve these negotiations on terms favorable to us, of which there can be no assurance, the resulting financial burden may adversely affect our business and may cause us to seek additional capital, which may not be available on terms acceptable to us, or at all.

We are at an early stage of development and we may not be able to successfully develop and commercialize our products and technologies.

The development of our products is subject to the risks of failure commonly experienced in the development of products based upon innovative technologies and the expense and difficulty of obtaining approvals from regulatory agencies. Drug discovery and development is time consuming, expensive and unpredictable. On average, only one out of many thousands of chemical compounds discovered by researchers proves to be both medically effective and safe enough to become an approved medicine. In the fields that we target, approximately one in ten compounds placed in clinical trials generally reaches the market. All of our proposed products are in the preclinical or early clinical stage of development and will require significant additional funding for research, development and clinical testing before we are able to submit them to any of the regulatory agencies for clearances for commercial use. If we are successful in negotiating a new license with the University of Illinois, we would have the rights to the data from a clinical trial that is being funded by third parties and do not involve financial commitments from us. Since we are not in control of such study, there is no assurance that it would be conducted in the same manner we would have conducted it had we provided the funding.

The process from discovery to development to regulatory approval can take several years and drug candidates can fail at any stage of the process. Late stage clinical trials often fail to replicate results achieved in earlier studies. Even if we do successfully complete such trials, we may not be able to market successfully any of the products or be able to obtain the necessary regulatory approvals or assure that healthcare providers and payors will accept our products. We also face the risk that any or all of our products will not work as intended or that they will be unsafe, or that, even if they do work and are safe, that our products will be uneconomical to manufacture and market on a large scale. Due to the extended testing and regulatory review process required before we can obtain marketing clearance, we do not expect to be able to commercialize any therapeutic drug for several years, either directly or through potential corporate partners or licensees.

We may not be able to enter into the strategic alliances necessary to fully develop and commercialize our products and technologies, and we will be dependent on our corporate partners if we do.

We intend to seek partners to assist in the development of our compounds. These agreements would potentially provide us with additional funds in exchange for exclusive or non-exclusive license or other rights to the technologies and products that we are currently developing. Competition between biopharmaceutical companies for these types of arrangements is intense. We cannot give any assurance that any future efforts on our part will result in an agreement or agreements in a timely manner, or at all. Additionally, we cannot assure you that any resulting agreement will generate sufficient revenues to offset our operating expenses and the costs of any required longer-term funding.

We may be unable to obtain additional capital or access to debt markets if needed to grow our business, which would adversely impact our business. If we raise additional financing, you may suffer significant dilution.

In the event of a maximum funding of $1,500,000, although we expect that this Offering will be sufficient to satisfy our operating requirements through approximately November 30, 2014, we expect that we will need to seek additional third-party investment in order to provide the working capital to finance existing operations and our growth plans. We cannot be certain that financing from third parties will be available on acceptable terms to us or at all. Our future capital requirements will depend upon several factors. If our capital requirements vary materially from those currently planned, we may require additional financing sooner than anticipated. If we cannot raise funds on acceptable terms, we may not be able to develop our products, take advantage of future opportunities, or respond to competitive pressures or unanticipated requirements, any of which could have a material adverse effect on our ability to grow our business. Further, if we issue additional equity securities or securities convertible into equity securities, holders of company equity, at that time, will experience dilution of their ownership percentages, and the new equity securities or convertible securities may have rights, preferences or privileges senior to our existing outstanding equity securities, including the Securities. Finally, if we are unsuccessful in bringing our SEC filings current and in subsequently maintaining them, that could have a material adverse effect on our ability to raise additional capital.

We are not in compliance with a Note held by one of our significant investors.

We are not in compliance with the terms of a secured promissory note (“Note”) dated June 25, 2012 in the amount of 465,000,000 KRW (approximately $437,000 as of November 21, 2013) issued to Samyang Optics Co. Ltd (“Samyang”), bearing interest at 12% per year. Principal and interest was due on June 25, 2013.

The related security agreement identifies the following patent applications as the collateral: (i) PCT/US07/26415; WO 2008/085505, (ii) PCT/US08/10877; WO 2009/038752, (iii) PCT/US08/009508; WO 009/023126, (iv) PCT/US2010/00255; WO 2010/087981 and (v) PCT/US2010/00254; WO 2010/087980. We do not believe filings under the Uniform Commercial Code (UCC) have been made in respect to such collateral.

We have commenced discussions with Samyang in respect to this Note and the License discussed in the following risk factor; however there can be no assurances that such discussions will be productive or that any requirement to pay amounts due under the note would not have adverse effects on our continued operation.

The counter party to one of the Licenses we hold is not in compliance with the terms of that License Agreement.

Samyang Optics Co. Ltd. is not in compliance with the terms of a license agreement (“License”) with us entered into on January 11, 2012 and amended on June 25, 2012, concurrently with the Note described above. The License defines the field to include neurodegenerative disorders including but not limited to Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis and Amyotrophic Lateral Sclerosis, as well as sleep apnea and respiratory depression. The licensed compound and related product relate to CX1739. There is a right to exclusively negotiate a license for CX1846. The License calls for a milestone payment by Samyang to us of $1,000,000 on the earlier of the dosing of a first patient in a Phase III clinical trial or December 31, 2015. The License calls for royalty payments ranging from 6% to 8%. The territory is initially, the Republic of Korea, but under certain circumstances, within the first year of the License, could have been expanded to include certain other Asian countries. Those conditions were not met and the territory has not been expanded. The License requires, among other things, that Samyang provide a development plan and annual reports, neither of which have been provided to us.

(b) Risks Related to Our Industry

If we fail to secure adequate intellectual property protection, it could significantly harm our financial results and ability to compete.

Our success will depend, in part, on our ability to obtain and maintain patent protection for our products and processes in the U.S. and elsewhere. We have filed and intend to continue to file patent applications as we need them. However, additional patents that may issue from any of these applications may not be sufficiently broad to protect our technology. Also, any patents issued to us or licensed by us may be designed around or challenged by others, and if such challenge is successful, it may diminish our rights.

If we are unable to obtain and maintain sufficient protection of our proprietary rights in our products or processes prior to or after obtaining regulatory clearances, our competitors may be able to obtain regulatory clearance and market competing products by demonstrating the equivalency of their products to our products. If they are successful at demonstrating the equivalency among the products, our competitors would not have to conduct the same lengthy clinical tests that we have conducted.

We also rely on trade secrets and confidential information that we try to protect by entering into confidentiality agreements with other parties. Those confidentiality agreements may be breached, and our remedies may be insufficient to protect the confidential information. Further, our competitors may independently learn our trade secrets or develop similar or superior technologies. To the extent that our consultants, key employees or others apply technological information independently developed by them or by others to our projects, disputes may arise regarding the proprietary rights to such information. We cannot assure you that such disputes will be resolved in our favor.

We may be subject to potential product liability claims. One or more successful claims brought against us could materially impact our business and financial condition.

The clinical testing, manufacturing and marketing of our products may expose us to product liability claims. Upon the initiation of clinical testing, we plan to obtain liability insurance with customary coverage limits. We have never been subject to a product liability claim, and we require each patient in our clinical trials to sign an informed consent agreement that describes the risks related to the trials, but we cannot assure you that the coverage limits of our insurance policies will be adequate or that one or more successful claims brought against us would not have a material adverse effect on our business, financial condition and result of operations. Further, if one of our compounds is approved by the FDA for marketing, we cannot assure you that adequate product liability insurance will be available, or if available, that it will be available at a reasonable cost. Any adverse outcome resulting from a product liability claim could have a material adverse effect on our business, financial condition and results of operations.

We face intense competition that could result in products that are superior to the products that we are developing.

Our business is characterized by intensive research efforts. Our competitors include many companies, research institutes and universities that are working in a number of pharmaceutical or biotechnology disciplines to develop therapeutic products similar to those we are currently investigating. Accordingly, it is possible that our competitors may succeed in developing products that are safer or more effective than those that we are developing and may obtain FDA approvals for their products faster than we can. We expect that competition in this field will continue to intensify.

We operate as a virtual company and may be unable to recruit and retain our senior management and other key technical personnel on whom we are dependent.

We are highly dependent upon senior management and key technical personnel and currently do not carry any insurance policies on such persons. In particular, we are highly dependent on our President and Chief Executive Officer, Arnold S. Lippa, Ph.D., our Chief Financial Officer, Robert N. Weingarten, and our Vice-President, Jeff E. Margolis. We are unable to pay them cash compensation for their services; they currently have agreed to accept equity compensation in lieu of cash compensation for a limited period of time, in amounts that have not yet been determined by the Company’s Board. Competition for qualified employees among pharmaceutical and biotechnology companies is intense. None of our officers are subject to employment agreements with the Company. The loss of any of our senior management, or our inability to attract, retain and motivate the additional highly-skilled employees and consultants that our business requires, could substantially hurt our business and prospects. Our Chief Executive Office, Arnold S. Lippa, devotes his full time professional efforts to the Company. Other directors and officers of the Company have business commitments and obligations other than with the Company and therefore do not currently devote their full time efforts to the Company; however, these directors and officers intend to devote as much support as is needed.

The regulatory approval process is expensive, time consuming, uncertain and may prevent us from obtaining required approvals for the commercialization of some of our products.

The FDA and other similar agencies in foreign countries have substantial requirements for therapeutic products. Such requirements often involve lengthy and detailed laboratory, clinical and post-clinical testing procedures and are expensive to complete. It often takes companies many years to satisfy these requirements, depending on the complexity and novelty of the product. The review process is also extensive, which may delay the approval process even more.

To date, we have not obtained any approvals to market our products. Further, we cannot assure you that the FDA or other regulatory agency will grant us approval for any of our products on a timely basis, if at all. Even if regulatory clearances are obtained, a marketed product is subject to continual review, and later discovery of previously unknown problems may result in restrictions on marketing or withdrawal of the product from the market.

We cannot guarantee that an investor will realize a return on their investment.

There is no assurance that a purchaser of Securities will realize a return on the investor’s investment or that such investor will not lose its entire investment. There can be no assurances that we will achieve profitable operations, or generate sufficient cash flow to operate successfully. Our ability to grow our business and establish profitable operations is dependent on the completion of this Offering, and potentially the completion of subsequent offerings of securities. There can be no assurance that we will receive adequate investment proceeds to fully implement our business plans or to allow us to achieve profitable operations.

Uncertainty of pro forma financial information and inability of historical information to be predictive of the future.

The pro forma financial information covering periods subsequent to June 30, 2012 and other financial information, including forward looking financial information contained in the materials provided to you, contains only a broad outline of potential future results and should not be considered as an indicator of future performance. Our publicly available filings with the SEC contain historical financial and other information, but may not be predictive of future events or results. The potential future results are based on assumptions made at the time such information was developed. There can be no assurances that the potential future results contained in the pro forma financial information will be obtained, and actual results may vary significantly from the pro forma financial information. General economic conditions, which are not predictable, can have a material adverse effect on the reliability and accuracy of such pro forma financial information, particularly over an extended period of time.

The transaction will authorize a significant number of shares which the Company intends to use, in part, to compensate officers and directors and, potentially, to pay vendors or other service providers, which would result in dilution of existing stockholders.

The Company intends that a portion of the increased shares authorized in the transaction would be used to compensate its directors and officers. In addition, certain shares may be used in negotiating payment of new or existing amounts owed to vendors, consultants, advisors, former officers and/or former directors or other parties that the Company has contracted with or will contract with. When the Company makes such issuances of stock, its existing stockholders, at that time, will experience dilution of their stock ownership percentages.

The Offering will be made on a “rolling” basis and we will have the right to close or suspend the Offering at any time for any reason in our sole discretion.

The Offering will commence on the date of this Memorandum and will continue until (i) we receive and accept up to $1,500,000 of investment proceeds for our Series G Preferred Stock, or (ii) the Company’s Board of Directors decides to terminate the Offering. We will have the right to begin closing on sales of our Series G Preferred Stock once all conditions precedent to closing are met, including but not limited to a minimum of $750,000 (the “ Minimum ”) being held in escrow with acceptance of associated Purchase Agreements, including amounts previously provided to the Company upon issuance of certain Secured Demand Promissory Note(s) (“ Notes ”), which Notes shall convert into the Offering. If we choose to end the offering before the maximum of $1,500,000 is reached, we may not later be able to raise additional capital on terms acceptable to us, or at all, which could adversely affect our business, and our ability to fund our operations beyond May 31, 2014 could also be adversely affected.

Our officers have broad discretion in the application of proceeds from this Offering, and broad discretion in the exercise of control of the day-to-day operations of our business.

Our officers will have broad discretion in the application of the proceeds of this Offering. As a result of the foregoing, our success will be substantially dependent upon the discretion and judgment of our officers in the application of the proceeds of this Offering. As such, our officers will essentially exercise control over our affairs, subject to approval by our board of directors. As a result of the foregoing, our success will also be substantially dependent upon the discretion and judgment of our directors and officers with respect to operational decisions. The stockholders of the Company, in their capacity as such, have no right to participate in the management of the Company or to otherwise participate in making decisions that affect the day-to-day business operations of the Company.

There is no assurance that we will achieve profitable operations or make payments on the Securities or distributions of profits to our Stockholders.

There is no assurance as to when or whether we will ever be profitable, or whether we will be able to return any investment funds, make cash distributions to our stockholders or meet our operating expenses. Management currently does not intend to declare any dividends, except as may be required pursuant to the Certificate of Designation of the Series G Preferred Stock (subject to compliance with applicable legal and tax rules and regulations), as we intend to invest all excess cash flow into our operations to fund our targeted growth. We will pay operating expenses and other costs prior to paying any dividends on the Securities. Even if dividends are declared and paid, there is no guarantee that any subsequent dividends will be declared and paid.

There is no public market for the Series G Preferred Stock and we do not expect such a market to develop in the future.

There is no public or other market for the Series G Preferred Stock and no such public market is ever expected to develop. Therefore, purchasers of the Series G Preferred Stock should anticipate that their investments will remain illiquid.

The transferability of the Securities is severely limited.

The Securities have not been registered under the Securities Act or the securities laws of the various states and the Securities may not be resold unless and until the sale is made under an effective registration statement under the Securities Act, and such state laws or exemptions from registration requirements are available. As a result, an investor must bear the economic risk of an investment in us for an indefinite period of time. No registration rights are being granted in connection with this Offering.

Future indebtedness could effectively rank senior to the Securities.

The Securities may be subordinated to future debt financings that the Company may enter into from time to time. The Company may not have sufficient assets remaining to pay amounts due on any or all of the Securities then outstanding. The Company will not be restricted from incurring additional indebtedness and other liabilities, or from pledging assets to secure such indebtedness and liabilities. The incurrence of additional indebtedness, and in particular the granting of a security interest to secure the indebtedness, could adversely affect the Company’s ability to pay its obligations relating to the Securities.

The Company’s Certificate of Incorporation requires amendment to increase the number of authorized shares of Common Stock available for issuance.

The Company’s Certificate of Incorporation currently authorizes the issuance of 205,000,000 shares of Common stock. In order for the Company to validly issue Conversion Shares, the Company’s Certificate of Incorporation must be amended to increase the number of authorized shares of Common Stock from the current 205,000,000 shares of Common Stock to a minimum of approximately 1,400,000,000 shares of Common Stock. The Company’s Certificate of Incorporation may only be amended with the approval of stockholders, voting together as a single class on an as converted basis, holding a majority of the outstanding shares of the Company’s capital stock. Unless the Charter Amendment or a similar amendment to the Company’s Certificate of Incorporation is approved, the Company will not be in a position to meet its commitment to issue an adequate number of Conversion Shares.

The ability of current senior management to make representations in the Offering is limited to “actual knowledge”.

The Company’s current senior management assumed their respective positions with the Company beginning in March 2013 when prior senior management was removed in their entirety, and current management’s knowledge of the Company’s history, including, but not limited to, its operations, assets, liabilities, commitments, capital structure and other business matters, is therefore limited. Accordingly, the phrase “to the Company’s knowledge” (and any similar phrasing) in this Agreement or with respect to any related schedule, exhibit, annex or other document, refers only to “actual knowledge” of current senior management at the Closing of the Offering, and is limited thereby.

The Securities are subject to mandatory conversion and mandatory redemption.

If not converted earlier, the Securities are subject to mandatory redemption on the two year anniversary of the date on which the last share of the Series G Preferred Stock is issued pursuant to this Agreement. In addition, the shares of Series G Preferred Stock are subject to mandatory conversion upon the consummation of any offering of equity securities, or debt securities convertible into equity securities, with aggregate gross proceeds to the Company of not less than $2,000,000.

The price of the Series G Preferred Stock has not been established in an arms-length negotiation.

The Company has not set the price of the Series G Preferred Stock through an arms-length negotiation with any Purchaser or Purchaser representative. The Company believes the price at which the Series G Preferred Stock is being offered appropriately reflects economic realities under the Company’s current circumstances, and in connection with this Offering, has obtained a fairness opinion to support this view, attached hereto as Exhibit D . However, there can be no assurances that the shares of Series G Preferred Stock are not worth substantially less than the price at which they are being offered.

(d) Other Risks

Our stock price may be volatile and our Common Stock could decline in value.

The market price of securities of life sciences companies in general has been very unpredictable. The range of sales prices of our Common Stock for the period from February 14, 2013 to February 17, 2014, as quoted on the Over the Counter Bulletin Board, was from $0.02 to $0.10. The range of sales prices of our Common Stock for the fiscal years ended December 31, 2012 and 2011, as quoted on the Over the Counter Bulletin Board, was from $0.02 to $0.11, and from $0.05 to $0.19, respectively. The following factors, in addition to factors that affect that market generally, could significantly impact our business, and cause a decline in the market price of our Common Stock:

1. competitors announcing technological innovations or new commercial products;

2. competitors’ publicity regarding actual or potential products under development;

3. regulatory developments in the U.S. and foreign countries;

4. developments concerning proprietary rights, including patent litigation;

5. public concern over the safety of therapeutic products; and

6. changes in healthcare reimbursement policies and healthcare regulations.

There are a large number of shares of the Company’s Common Stock that may be issued or sold, and if such shares are issued or sold, the market price of our Common Stock may decline.

As of August 13, 2012, we had approximately 144,000,000 shares of our Common Stock issued and outstanding.

If all warrants and options potentially outstanding as of November 13, 2013 were exercised prior to their expiration, up to 18,532,776 additional shares of our Common Stock could become freely tradable. As mentioned elsewhere in this Agreement, certain of these outstanding warrants and options have exercise prices above (and in many cases significantly above) the recent trading price range of the Company’s Common Stock. It is also possible that, under certain circumstances, up to an additional 15,305,867 (subject to reduction for options included in the potential total above that may have expired) of “contingent” shares associated with the Pier Pharmaceuticals, Inc. merger agreement may be issued. Such sales or issuances of substantial amounts of Common Stock could adversely affect the prevailing market price of our Common Stock and could also make it more difficult for us to raise funds through future offerings of Common Stock.

Our charter document may prevent or delay an attempt by our stockholders to replace or remove management.

Certain provisions of our Certificate of Incorporation, as amended, could make it more difficult for a third party to acquire control of our business, even if such change in control would be beneficial to our stockholders. Our Certificate of Incorporation, as amended, allows the Board of Directors of the Company to issue up to an additional 3,507,500 shares of preferred stock without stockholder approval. The ability of our Board of Directors to issue additional preferred stock may have the effect of delaying or preventing an attempt by our stockholders to replace or remove existing directors and management.

If our Common Stock is a “penny stock,” a broker-dealer may find it more difficult to trade our Common Stock and an investor may find it more difficult to acquire or dispose of our Common Stock in the secondary market.

Our Common Stock is currently subject to the so-called “penny stock” rules. The SEC has adopted regulations that define a “penny stock” to be any equity security that has a market price per share of less than $5.00, subject to certain exceptions, such as any securities listed on a national securities exchange. For any transaction involving a “penny stock,” unless exempt, the rules impose additional sales practice requirements on broker-dealers, subject to certain exceptions. As our Common Stock is “penny stock,” a broker-dealer may find it more difficult to trade our Common Stock and an investor may find it more difficult to acquire or dispose of our Common Stock on the secondary market.

We are delinquent in our filings with the SEC subsequent to June 30, 2012.

Our reporting obligations pursuant to SEC rules and regulations have been and continue to be delinquent subsequent to June 30, 2012. Our current management, who joined the Company in March and April 2013, currently intend to bring the Company’s SEC reporting obligations current by April 2014. However, at this time, we are unable to provide assurances that we will regain current SEC filing reporting status. As a result, the ability of our stockholders to utilize SEC Rule 144 for an indeterminate period of time may be adversely affected. We currently are not permitted and may not be permitted in the future to, among other things, file and have declared effective registration statements to effect public offerings of our securities.

The SEC may seek to revoke the Company’s registration under the Securities Exchange Act of 1934 or to suspend trading in the Company’s Common Stock until the Company is current in its filings, or longer.

In a letter dated November 7, 2013 from the SEC, the SEC informed the Company that it believed that the Company was not current in its required filings and that if not current, the Company should file the required reports within fifteen (15) days of the date of the letter. The SEC warned that the Company may be the subject of an administrative proceeding to revoke its registration under the Securities Exchange Act of 1934. Furthermore, trading in the Company’s stock may be suspended until the Company is current in its filings, or longer. The Company has been in contact with the SEC and has presented its intended schedule to bring its filings current. The Company intends to meet these milestones; however, there can be no assurances regarding what, if any, actions the SEC will choose to take and when it may take them.

Our Common Stock trades on the OTCPink®, bears a designation that limited information is available and trading may be volatile and sporadic, which could depress the market price of our Common Stock and make it difficult for our stockholders to resell their Common Stock.

Our Common Stock is quoted on the OTCPink® which also has a designation that limited information is available. Trading in stocks quoted on the OTCPink® is often thin and characterized by wide fluctuations in trading prices with large bid and ask spreads, due to many factors that may have little to do with our operations or business prospects. This volatility could depress the market price of our Common Stock for reasons unrelated to operating performance. Moreover, the OTCPink® is not a stock exchange, and trading of securities on the OTCPink® is often more sporadic than the trading of securities listed on a quotation system like NASDAQ or a stock exchange like the NYSE. Accordingly, stockholders may have difficulty reselling any of their shares of Common Stock.

3. PURCHASER’S REPRESENTATIONS AND WARRANTIES.

Each Purchaser severally, but not jointly, represents and warrants to the Company as follows:

(a) Purchase for Own Account. Such Purchaser is purchasing the Series G Preferred Stock for such Purchaser’s own account for investment purposes only and not with a present view towards the public sale or distribution thereof, except pursuant to sales that are exempt from the registration requirements of the Securities Act and/or sales registered under the Securities Act. Such Purchaser understands that such Purchaser must bear the economic risk of this investment indefinitely, unless the Securities are registered pursuant to the Securities Act and any applicable state securities or blue sky laws or an exemption from such registration is available, and that the Company has no present intention of registering the resale of any such Securities. Further, (i) the Purchaser has the requisite corporate (or other entity) or individual (as the case may be) power, capacity and authority to enter into and perform his, her or its obligations under this Agreement and the Certificate of Designation, to purchase the Series G Preferred Stock in accordance with the terms hereof, to hold beneficially and of record and to receive the Conversion Shares upon conversion of the Series G Preferred Stock in accordance with the terms thereof; (ii) the execution, delivery and performance of this Agreement and the consummation by it of the transactions contemplated hereby have been duly authorized and no further consent or authorization is required, and (iii) this Agreement constitutes valid and binding obligations of the Purchaser enforceable against the Purchaser in accordance with its terms except as enforceability of the obligations under this Agreement may be limited by (A) bankruptcy, insolvency, moratorium or other similar laws affecting creditors’ rights generally, and (B) general principles of equity relating to the availability of equitable remedies (whether such agreements are sought to be enforced in a proceeding at law or a proceeding in equity).

(b) Accredited Investor Status, Not a Financial Bad Actor, Suitability and Risks . Such Purchaser is an “Accredited Investor” as that term is defined in Rule 501(a) of Regulation D. Additionally, Purchaser represents that Purchaser is not a “felon or other bad actor” as defined in the Dodd-Frank Act. Purchaser represents that an investment in the Company is suitable for such Purchaser. Purchaser understands the very significant risks associated with an investment in the Company and represents that such Purchaser understands that such Purchaser may suffer a loss of Purchaser’s entire investment and Purchaser further represents that such Purchaser has the financial capacity to withstand such loss. In connection with this Offering, such Purchaser has completed an investor questionnaire supporting his, her or its status as an Accredited Investor. All information provided in such questionnaire is true, complete and accurate.

(c) Reliance on Exemptions . Such Purchaser understands that the Securities are being offered and sold to such Purchaser in reliance upon specific exemptions from the registration requirements of United States federal and state securities laws and that the Company is relying upon the truth and accuracy of, and such Purchaser’s compliance with, the representations, warranties, agreements, acknowledgments and understandings of such Purchaser set forth herein in order to determine the availability of such exemptions and the eligibility of such Purchaser to acquire the Securities. Purchaser agrees to provide copies of documents reasonably requested by the Company in order for the Company to obtain reasonable assurance that Purchaser is an Accredited Investor.

(d) Information . All materials relating to the business, finances and operations of the Company and materials relating to the offer and sale of the Securities, including without limitation the fairness opinion obtained by the Company in connection with the transaction, which have been specifically requested by such Purchaser or its counsel and which are reasonably available have been made available to such Purchaser or its counsel. The Company shall not be liable in any respect with respect to any liabilities, losses, damages, penalties, actions, judgments, suits, costs, expenses or disbursements of any kind and nature whatsoever arising out of matters within the knowledge of Purchaser. Such Purchaser understands that such Purchaser’s investment in the Securities involves a high degree of risk.

(e) Governmental Review . Such Purchaser understands that no United States federal or state agency or any other government or governmental agency has passed upon or made any recommendation or endorsement of the Securities.

(f) Authorization; Enforcement . This Agreement has been duly and validly authorized, executed and delivered on behalf of such Purchaser and is a valid and binding agreement of such Purchaser enforceable against such Purchaser in accordance with its terms.

(g) Residency . Such Purchaser is a resident of the jurisdiction set forth under such Purchaser’s name on the Execution Page hereto executed by such Purchaser.

Each Purchaser’s representations and warranties made in this Article 3 are made in part for the purpose of permitting the Company to make a determination that the offer and sale of the Securities pursuant to this Agreement comply with applicable U.S. federal and state securities laws. No Purchaser has made or hereby makes any other representations or warranties, express or implied, to the Company in connection with the transactions contemplated hereby. Each Purchaser acknowledges that such Purchaser understands the meaning and legal consequences of the representations and warranties contained herein, and such Purchaser hereby agrees to indemnify and hold harmless the Company and the directors, officers, employees and agents of the Company from and against any and all loss, damage or liability (including costs and reasonable attorney fees) due to or arising out of a breach of any representation, warranty, agreement or acknowledgment of such Purchaser contained in this Agreement or arising out of the sale of the Series G Preferred Stock, the Securities Act or any other applicable state or federal securities law.

4. REPRESENTATIONS AND WARRANTIES OF THE COMPANY.

Except as set forth on a Disclosure Schedule (the “ Disclosure Schedule ”), executed and delivered by the Company to each Purchaser or as set forth in those reports and schedules filed by the Company with the SEC pursuant to the Securities Exchange Act of 1934, as amended (the “ SEC Reports ”), the Company represents and warrants to each Purchaser as follows:

(a) Organization and Qualification . The Company and each of its direct and indirect subsidiaries (collectively, the “ Subsidiaries ”) is a corporation duly organized and existing in good standing under the laws of the jurisdiction in which it is incorporated or organized, and has the requisite corporate power to own its properties and to carry on its business as now being conducted. The Company and each of its Subsidiaries is duly qualified as a foreign corporation to do business and is in good standing in every jurisdiction in which the nature of the business conducted by it makes such qualification necessary and where the failure so to qualify or be in good standing would have a Material Adverse Effect. For purposes of this Agreement, “ Material Adverse Effect ” means any effect which, individually or in the aggregate with all other effects, reasonably would be expected to be materially adverse to (i) the Securities, (ii) the ability of the Company to perform its obligations under this Agreement or the Certificate of Designation or (iii) the business, operations, properties, financial condition or results of operations of the Company and its Subsidiaries, taken as a whole.

(b) Authorization; Enforcement . (i) The Company has the requisite corporate power and authority to enter into and perform its obligations under this Agreement and the Certificate of Designation, to issue and sell the Series G Preferred Stock in accordance with the terms hereof, to issue the Conversion Shares upon conversion of the Series G Preferred Stock in accordance with the terms thereof, subject to the successful completion of the Written Consent; (ii) the execution, delivery and performance of this Agreement and the Certificate of Designation by the Company and the consummation by it of the transactions contemplated hereby (including, without limitation, the issuance of the Series G Preferred Stock and the issuance and reservation for issuance of the Conversion Shares, subject to the successful completion of the Written Consent) have been duly authorized by the Company’s Board of Directors and no further consent or authorization of the Company, its Board of Directors, or any committee of the Board of Directors or the stockholders of the Company is required, and (iii) this Agreement and the Certificate of Designation constitute valid and binding obligations of the Company enforceable against the Company in accordance with their respective terms except as enforceability of the obligations under this Agreement or the Certificate of Designation may be limited by (A) bankruptcy, insolvency, moratorium or other similar laws affecting creditors’ rights generally, and (B) general principles of equity relating to the availability of equitable remedies (whether such agreements are sought to be enforced in a proceeding at law or a proceeding in equity).

(c) Capitalization . To the Company’s knowledge, the capitalization of the Company as of August 10, 2012, including the authorized capital stock, the number of shares issued and outstanding, the number of shares issuable and reserved for issuance pursuant to the Company’s stock option plans, the number of shares issuable and reserved for issuance pursuant to securities (other than the Series G Preferred Stock) exercisable or exchangeable for, or convertible into, any shares of capital stock and the number of shares to be reserved for issuance upon conversion of the Series G Preferred Stock is set forth in Section 4(c) of the Disclosure Schedule. To the Company’s knowledge, there has been no change to the capitalization of the Company since August 10, 2012, except as set forth in Section 4(c) of the Disclosure Statement. All of such outstanding shares of capital stock have been, or upon issuance in accordance with the terms of any such exercisable, exchangeable or convertible securities will be, validly issued, fully paid and non-assessable. To the Company’s knowledge, no shares of capital stock of the Company (including the Conversion Shares) are subject to preemptive rights or any other similar rights of the stockholders of the Company or any liens or encumbrances. Except for the Securities and as set forth in Section 4(c) of the Disclosure Schedule, to the Company’s knowledge, (i) there are no outstanding options, warrants, scrip, rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities or rights convertible into or exercisable or exchangeable for, any shares of capital stock of the Company or any of its Subsidiaries, or contracts, commitments, understandings or arrangements by which the Company or any of its Subsidiaries is or may become bound to issue additional shares of capital stock of the Company or any of its Subsidiaries, nor are any such issuances, contracts, commitments, understandings or arrangements contemplated, (ii) there are no contracts, commitments, understandings or arrangements under which the Company or any of its Subsidiaries is obligated to register the sale of any of its or their securities under the Securities Act; (iii) there are no outstanding securities or instruments of the Company or any of its Subsidiaries which contain any redemption or similar provisions, and there are no contracts, commitments, understandings or arrangements by which the Company or any of its Subsidiaries is or may become bound to redeem or otherwise acquire any security of the Company or any of its Subsidiaries; and (iv) the Company does not have any stockholder rights plan, “poison pill” or other anti-takeover plans or similar arrangements, although provisions permitting the Board of Directors to issue preferred stock with terms and conditions at its discretion without shareholder approval may enable the Board of Directors to discourage takeover plans or similar arrangements. To the Company’s knowledge, Section 4(c) of the Disclosure Schedule sets forth all of the securities or instruments issued by the Company or any of its Subsidiaries that contain anti-dilution or similar provisions, and, except as and to the extent set forth thereon, the sale and issuance of the Securities will not trigger any anti-dilution adjustments to any such securities or instruments. The Company has made available to each Purchaser true and correct copies of the Company’s Certificate of Incorporation as in effect on the date hereof (“ Certificate of Incorporation ”), the Company’s Bylaws as in effect on the date hereof (the “ Bylaws ”), and, to the Company’s knowledge, all other instruments and agreements governing securities convertible into or exercisable or exchangeable for capital stock of the Company, all of which instruments and agreements, to the Company’s knowledge, are set forth in Section 4(c) of the Disclosure Schedule. The Company or one of its Subsidiaries has the unrestricted right to vote, and (subject to limitations imposed by applicable law) to receive dividends and distributions on, all capital securities of its Subsidiaries as owned by the Company or any such Subsidiary.

(d) Issuance of Securities . The shares of Series G Preferred Stock are duly authorized and, upon issuance in accordance with the terms of this Agreement, (i) will be validly issued, fully paid and non-assessable and free from all taxes, liens, claims and encumbrances (except for such encumbrances imposed by applicable securities laws) and (ii) will not be subject to preemptive rights, rights of first refusal or other similar rights of stockholders of the Company or any other person. The Conversion Shares are duly authorized and, subject to successful implementation of the Written Consent, reserved for issuance, and, upon conversion of the Series G Preferred Stock in accordance with the terms thereof, (x) will be validly issued, fully paid and non-assessable, and free from all taxes, liens, claims and encumbrances, and (y) will not be subject to preemptive rights, rights of first refusal or other similar rights of stockholders of the Company or any other person.

(e) No Conflicts; Consents . Except as set forth in Section 4(e) of the Disclosure Schedule, the execution, delivery and performance of this Agreement by the Company and the consummation by the Company of the transactions contemplated hereby (including, without limitation, the issuance of the shares of Series G Preferred Stock and the issuance and reservation for issuance of the Conversion Shares) will not, to the Company’s knowledge, (i) result in a violation of the Certificate of Incorporation or Bylaws, (ii) conflict with, or constitute a default (or an event that with notice or lapse of time or both would become a default) under, or give to others any rights of termination, amendment (including, without limitation, the triggering of any anti-dilution provisions), acceleration or cancellation of, any agreement, indenture or instrument to which the Company or any of its Subsidiaries is a party, or (iii) result in a violation of any law, rule, regulation, order, judgment or decree (including United States federal and state securities laws, rules and regulations and rules and regulations of any self-regulatory organizations to which either the Company or its securities are subject) applicable to the Company or any of its Subsidiaries or by which any property or asset of the Company or any of its Subsidiaries is bound or subject (except, with respect to clauses (ii) and (iii), for such conflicts, defaults, terminations, amendments, accelerations, cancellations and violations that would not, individually or in the aggregate, have a Material Adverse Effect). Except (x) for the filing of a Form D with the SEC, (y) as may be required for compliance with applicable state securities or “blue sky” laws, or (z) as otherwise set forth in Section 4(e) of the Disclosure Schedule, to the Company’s knowledge, the Company is not required to obtain any consent, approval, authorization or order of, or make any filing or registration with, any court or governmental agency or any regulatory or self-regulatory agency or other third party (including, without limitation, pursuant to any and all material, undischarged written or oral contracts, agreements, leases or other instruments to which the Company or any Subsidiary is a party or by which the Company or any Subsidiary is bound or to which any of the properties or assets of the Company or any Subsidiary is subject (each, a “ Material Contract ”)) in order for it to execute, deliver or perform any of its obligations under this Agreement.

(f) Compliance . To the Company’s knowledge, the Company is not in violation of its Certificate of Incorporation, Bylaws or other organizational documents and no Subsidiary is in violation of any of its organizational documents. Except as set forth in Section 4(f) of the Disclosure Schedule, to the Company’s knowledge, neither the Company nor any of its Subsidiaries is in default (and no event has occurred that with notice or lapse of time or both would put the Company or any of its Subsidiaries in default) under, nor has there occurred any event giving others (with notice or lapse of time or both) any rights of termination, amendment, acceleration or cancellation of, any agreement, indenture or instrument to which the Company or any of its Subsidiaries is a party (including, without limitation, the Material Contracts). To the Company’s knowledge, the businesses of the Company and its Subsidiaries are not being conducted in violation of any law, ordinance or regulation of any governmental entity, except for possible violations the sanctions for which either individually or in the aggregate have not had or would not have a Material Adverse Effect. Since March 22, 2013, neither the Company, nor any of its Subsidiaries, nor any director, officer, agent, employee or other person acting on behalf of the Company or any Subsidiary has, in the course of his actions for, or on behalf of, the Company or any Subsidiary, used any corporate funds for any unlawful contribution, gift, entertainment or other unlawful expenses relating to political activity, made any direct or indirect unlawful payment to any foreign or domestic government official or employee from corporate funds, violated or is in violation of any provision of the U.S. Foreign Corrupt Practices Act of 1977, or made any bribe, rebate, payoff, influence payment, kickback or other unlawful payment to any foreign or domestic government official or employee. To the Company’s knowledge, the Company and its Subsidiaries possess all certificates, authorizations and permits issued by the appropriate federal, state, provincial or foreign regulatory authorities that are material to the conduct of its business, and neither the Company nor any of its Subsidiaries has received any notice of any proceeding relating to the revocation or modification of any such certificate, authorization or permit.

(g) SEC Documents, Financial Statements . Except as set forth in Section 4(g) of the Disclosure Schedule, from December 31, 2006 through November 1, 2012, the Company timely filed (within applicable extension periods) all reports, schedules, forms, statements and other documents required to be filed by it with the SEC pursuant to the reporting requirements of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”) (all of the foregoing filed prior to the date hereof and all exhibits included therein and financial statements and schedules thereto and documents incorporated by reference therein, the “ SEC Documents ”). To the Company’s knowledge, each of the SEC Documents did not, at the later of the time it was filed or the time at which it was subsequently amended prior to the date hereof, contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements made therein, in the light of the circumstances under which they were made, not misleading. The Company has not filed its Form 10-Q for the period ended September 30, 2012, its Form 10-K for the period ended December 31, 2012, or its Form 10-Qs for the periods ended March 31, 2013, June 30, 2013 and September 30, 2013.

(h) Transactions With Affiliates . Except as set forth in Section 4(h) of the Disclosure Schedule, none of the officers, directors, or employees of the Company or any of its Subsidiaries is presently a party to any transaction with the Company or any of its Subsidiaries (other than for ordinary course services solely in their capacity as officers, directors or employees), including any contract, agreement or other arrangement providing for the furnishing of services to or by, providing for rental of real or personal property to or from, or otherwise requiring payments to or from any such officer, director or employee or any corporation, partnership, trust or other entity in which any such officer, director, or employee has an ownership interest of five percent or more or is an officer, director, trustee or partner.

(i) Absence of Litigation . Except as set forth in Section 4(i) of the Disclosure Schedules, to the Company’s knowledge, there is no action, suit, proceeding, inquiry or investigation before or by any court, public board, government agency, self-regulatory organization or body pending or threatened against the Company, any of its Subsidiaries, or any of their respective directors or officers in their capacities as such except as would not reasonably be expected to have a Material Adverse Effect.

(j) Intellectual Property . Except as set forth in Section 4(j) of the Disclosure Schedule, to the Company’s knowledge, each of the Company and its Subsidiaries owns or is duly licensed (and, in such event, has the unfettered right to grant sublicenses) to use all patents, and patent applications (collectively, “ Intangibles ”) necessary for the conduct of its business as now being conducted and as presently contemplated to be conducted in the future. Section 4(j) of the Disclosure Schedule sets forth a list of all Intangibles owned and/or used by the Company in its business. To the knowledge of the Company and its Subsidiaries, neither the Company nor any Subsidiary of the Company infringes or is in conflict with any right of any other person with respect to any third party Intangibles except as would not reasonably be expected to have a Material Adverse Effect. To the knowledge of the Company and its Subsidiaries, neither the Company nor any Subsidiary of the Company has received written notice of any pending conflict with or infringement upon such third party Intangibles. To the Company’s knowledge, the Intangibles are valid and enforceable except as would not reasonably be expected to have a Material Adverse Effect and, except as set forth in Section 4(j) of the Disclosure Schedule, no registration relating thereto has lapsed, expired or been abandoned or canceled or is the subject of cancellation or other adversarial proceedings, and, all applications therefor are pending and in good standing. Except as set forth in Section 4(j) of the Disclosure Schedule, to the Company’s knowledge, the Company and its Subsidiaries have complied, in all material respects, with their respective contractual obligations relating to the protection of the Intangibles used pursuant to licenses. Except as set forth in Section 4(j) of the Disclosure Schedule, to the Company’s knowledge, no person is infringing on or violating the Intangibles owned or used by the Company or its Subsidiaries.

(k) Employee Relations . Except as set forth in Section 4(k)(i) of the Disclosure Schedule, neither the Company nor any of its Subsidiaries is involved in any material labor dispute nor, to the knowledge of the Company or any of its Subsidiaries, is any such dispute threatened. To the Company’s knowledge, set forth in Section 4(k)(ii) of the Disclosure Schedule is a true and complete list of any and all amounts due and owing, or allegedly due and owing but disputed, to any current or former employee of the Company as of the date set forth on such schedule.

(l) Insurance . The Company’s only insurance policy in effect is a Directors and Officers Liability Insurance policy. Except for that policy, neither the Company nor any of its Subsidiaries has in force fire, casualty, product liability or other insurance policies. To the Company’s knowledge, no material default or event has occurred that could reasonably be expected to give rise to a material default under such policy.

(m) Anti-Takeover Provisions . The Company and its board of directors have taken all necessary action, if any, in order to render inapplicable any control share acquisition, business combination, poison pill (including any distribution under a rights agreement) or other similar anti-takeover provision under its Certificate of Incorporation or the laws of the state of its incorporation which is or could become applicable to any Purchaser as a result of the transactions contemplated by this Agreement, including, without limitation, the Company’s issuance of the Securities and any and all Purchaser’s ownership of the Securities.

(n) Acknowledgment Regarding Each Purchaser’s Purchase of the Securities . The Company acknowledges and agrees that this Agreement and the transactions contemplated hereby were reached in arm’s length negotiations with the Purchasers, and, except as set forth in Section 4(n) to the Disclosure Schedule, that no Purchaser is an officer or director of the Company. The Company further acknowledges that no Purchaser is acting as a financial advisor or fiduciary of the Company (or in any similar capacity) with respect to this Agreement and the transactions contemplated hereby, and any advice given by a Purchaser or any of its representatives or agents in connection with this Agreement and the transactions contemplated hereby is merely incidental to such Purchaser’s purchase of the Securities. The Company further represents to each Purchaser that the Company’s decision to enter into this Agreement has been based solely on the independent evaluation by the Company and its representatives.

(o) Brokers and Finder’s Fees . At the Company’s sole discretion, the Company may pay a brokerage commission, finder’s fee or similar payment of up to 7% of the aggregate Purchase Price to any qualified referral source to which it can legally make such payment, in the form of either cash, the Securities, or shares of Common Stock, or any combination thereof, plus five year warrants to purchase up to that number of shares of Common Stock that is equal to 7% of the maximum number of Conversion Shares, at an exercise price equal to 120% of the Conversion Price. Officers, directors and affiliates of the Company (including affiliates of the Company’s officers and directors) are not eligible to receive such fees, directly or indirectly.

(p) Disclosure . To the Company’s knowledge, all information relating to or concerning the Company and/or any of its Subsidiaries set forth in this Agreement or provided to the Purchasers pursuant to Section 3(d) hereof or otherwise in connection with the transactions contemplated hereby is true and correct in all material respects. To the Company’s knowledge, the Company has not omitted to state any material fact necessary in order to make the statements made herein or therein, in light of the circumstances under which they were made, not misleading.

(q) No Other Representations or Warranties . Except for the express representations and warranties contained in this Section 4, neither the Company nor any other Person has made or makes any other express or implied representation or warranty, either written or oral, on behalf of the Company, including any representation or warranty as to the accuracy or completeness of any information regarding the Company furnished or made available to Purchaser and its representatives (including any information, documents or material made available to Buyer in management presentations, slide presentations or in any other form in expectation of the transactions contemplated hereby, including without limitation any such materials distributed with this Agreement) or as to the future revenue, profitability or success of the Company, or any representation or warranty arising from statute or otherwise in law.

5. COVENANTS .

(a) Form D; Blue Sky Laws . The Company shall file with the SEC a Form D with respect to the Securities as required under Regulation D and provide a copy thereof to each Purchaser upon written request promptly after such filing. The Company has or shall have, on or before the Closing Date, taken such action as the Company reasonably determined is necessary to qualify the Securities for sale to each Purchaser pursuant to this Agreement under applicable securities or “blue sky” laws of the states of the United States or obtain exemption therefrom, and shall provide evidence of any such action so taken to each Purchaser upon written request on or prior to the Closing Date or, if permitted by applicable law, after the Closing date, but within the timeframes prescribed by such applicable law. Within four business days after the Closing Date, the Company shall file a Form 8-K with the SEC concerning this Agreement and the transactions contemplated hereby, which Form 8-K shall attach this Agreement and its Exhibits as exhibits to such Form 8-K (the “ 8-K Filing” ).

(b) Use of Proceeds . The Company shall use the proceeds from the sale and issuance of the Series G Preferred Stock for general corporate purposes and working capital.

(c) Information . So long as any Purchasers (or any of their respective affiliates) beneficially own any of the Securities, the Company shall keep at its principal executive office a true copy of this Agreement (as at the time in effect), and cause the same to be available for inspection at such office during normal business hours by any holder of Securities or any prospective transferee of Securities designated by a holder thereof.

(d) Inspection of Properties and Books . So long as any Purchasers (or any of their respective affiliates) beneficially own any of the Securities, each such Purchaser and its representatives and agents (collectively, the “ Inspectors ”) shall have the right, at such Purchaser’s expense, to visit and inspect any of the properties of the Company and of its Subsidiaries, to examine the books of account and records of the Company and of its Subsidiaries, to make or be provided with copies and extracts therefrom, to discuss the affairs, finances and accounts of the Company and of its Subsidiaries with, and to be advised as to the same by, its and their officers, employees and independent public accountants (and by this provision the Company authorizes such accountants to discuss such affairs, finances and accounts, whether or not a representative of the Company is present) all at such reasonable times and intervals and to such reasonable extent as the Purchasers may desire; provided , however , that each Inspector shall hold in confidence and shall not make any disclosure (except to such Purchaser) of any such information which the Company determines in good faith to be confidential, and of which determination the Inspectors are so notified, unless (i) the disclosure of such information is necessary to avoid or correct a misstatement or omission in any registration statement filed, (ii) the release of such information is ordered pursuant to a subpoena or other order from a court or government body of competent jurisdiction, or (iii) such information has been made generally available to the public other than by disclosure in violation of this or any other agreement. Each Purchaser agrees that it shall, upon learning that disclosure of such information is sought in or by a court or governmental body of competent jurisdiction or through other means, give prompt notice to the Company and allow the Company, at its expense, to undertake appropriate action to prevent disclosure of, or to obtain a protective order for, the information deemed confidential.

6. SECURITIES TRANSFER MATTERS.

(a) Conversion and Exercise . Upon conversion of the Series G Preferred Stock by any person, (i) if the DTC Transfer Conditions (as defined below) are satisfied, the Company shall cause its transfer agent to electronically transmit all Conversion Shares by crediting the account of such person or its nominee with the Depository Trust Company (“ DTC ”) through its Deposit Withdrawal Agent Commission system; or (ii) if the DTC Transfer Conditions are not satisfied, the Company shall issue and deliver, or instruct its transfer agent to issue and deliver, certificates (subject to the legend and other applicable provisions hereof and the Certificate of Designation), registered in the name of such person its nominee, physical certificates representing the Conversion Shares. Even if the DTC Transfer Conditions are satisfied, any person effecting a conversion of Series G Preferred Stock may instruct the Company to deliver to such person or its nominee physical certificates representing the Conversion Shares in lieu of delivering such shares by way of DTC Transfer. For purposes of this Agreement, “ DTC Transfer Conditions ” means that (A) the Company’s transfer agent is participating in the DTC Fast Automated Securities Transfer program and (B) the certificates for the Conversion Shares required to be delivered do not bear a legend and the person effecting such conversion or exercise is not then required to return such certificate for the placement of a legend thereon.

(b) Transfer or Resale . Each Purchaser understands that (i) the sale or resale of the Securities have not been and are not being registered under the Securities Act or any state securities laws, and the Securities may not be transferred unless (A) the transfer is made pursuant to and as set forth in an effective registration statement under the Securities Act covering the Securities; or (B) such Purchaser shall have delivered to the Company an opinion of counsel (which opinion shall be in form, substance and scope customary for opinions of counsel in comparable transactions and reasonably acceptable to the Company) to the effect that the Securities to be sold or transferred may be (x) sold or transferred pursuant to an exemption from such registration, or (y) sold under and in compliance with Rule 144; or (C) sold or transferred to an affiliate of such Purchaser that agrees to sell or otherwise transfer the Securities only in accordance with the provisions of this Section 5(b) ; and (ii) neither the Company nor any other person is under any obligation to register such Securities under the Securities Act or any state securities laws. Notwithstanding the foregoing or anything else contained herein to the contrary, the Securities may be pledged as collateral in connection with a bona fide margin account, provided such pledge is consistent with applicable laws, rules and regulations. Furthermore, each Purchaser understands that in a letter dated November 7, 2013 from the SEC, the SEC informed the Company that it believed that the Company was not current in its required filings and that if not current, the Company should file the required reports within fifteen (15) days of the date of the letter. The SEC warned that the Company may be the subject of an administrative proceeding to revoke its registration under the Securities Exchange Act of 1934. Furthermore, trading in the Company’s stock may be suspended until the Company is current in its filings, or longer. The Company has been in contact with the SEC and has presented its intended schedule to bring its filings current. The Company intends to meet these milestones; however, there can be no assurances regarding what, if any, actions the SEC will choose to take and when it may take them.

(c) Legends . Each Purchaser understands that the Series G Preferred Stock and, until such time as the Conversion Shares have been registered under the Securities Act (including registration pursuant to Rule 416 thereunder) or may be sold by such Purchaser under Rule 144, the certificates for the Conversion Shares may bear a restrictive legend in substantially the following form in addition to any other legends required by applicable state securities laws:

The securities represented by this certificate have not been registered under the Securities Act of 1933, as amended, or the securities laws of any state of the United States or in any other jurisdiction. The securities represented hereby may not be offered, sold or transferred in the absence of an effective registration statement for the securities under applicable securities laws or an opinion of counsel in a form reasonably satisfactory to the company that such registration is not required under the Securities Act of 1933, as amended.

The Company shall, immediately prior to a registration statement covering the Securities being declared effective, deliver to its transfer agent an opinion letter of counsel, opining that at any time such registration statement is effective, the transfer agent shall issue, in connection with the issuance of the Conversion Shares, certificates representing such Conversion Shares without the restrictive legend above, provided such Conversion Shares are to be sold pursuant to the prospectus contained in such registration statement. Upon receipt of such opinion, the Company shall cause the transfer agent to confirm, for the benefit of the holders, that no further opinion of counsel is required at the time of transfer in order to issue such shares without such restrictive legend.

The legend set forth above shall be removed and the Company shall issue a certificate without such legend to the holder of any Security upon which it is stamped, if, unless otherwise required by state securities laws, (i) the sale of such Security is registered under the Securities Act (including registration pursuant to Rule 416 thereunder); (ii) such holder provides the Company with an opinion of counsel, in form, substance and scope customary for opinions of counsel in comparable transactions and reasonably acceptable to the Company, to the effect that a public sale or transfer of such Security may be made without registration under the Securities Act; or (iii) such holder provides the Company with reasonable assurances that such Security can be sold under Rule 144, including an opinion of counsel, in form, substance and scope customary for opinions of counsel in comparable transactions and reasonably acceptable to the Company. In the event the above legend is removed from any Security and thereafter the effectiveness of a registration statement covering such Security is suspended or the Company determines that a supplement or amendment thereto is required by applicable securities laws, then upon reasonable advance written notice to such Purchaser the Company may require that the above legend be placed on any such Security that cannot then be sold pursuant to an effective registration statement or under Rule 144 and such Purchaser shall cooperate in the replacement of such legend. Such legend shall thereafter be removed when such Security may again be sold pursuant to an effective registration statement or under Rule 144.

(d) Transfer Agent Instruction . Upon compliance by any Purchaser with the provisions of this Section 5 with respect to the transfer of any Securities, the Company shall permit the transfer of such Securities and, in the case of the transfer of Conversion Shares, promptly instruct its transfer agent to issue one or more certificates (or effect a DTC Transfer) in such name and in such denominations as specified by such Purchaser. The Company shall not give any instructions to its transfer agent with respect to the Securities, other than any permissible or required instructions provided in this Section 6 , and the Securities shall otherwise be freely transferable on the books and records of the Company as and to the extent provided in this Agreement.

7. CONDITIONS TO THE COMPANY’S OBLIGATION TO SELL.

The obligation of the Company hereunder to issue and sell the shares of Series G Preferred Stock to each Purchaser hereunder is subject to the satisfaction, at or before the Closing Date, of each of the following conditions as to such Purchaser, provided that such conditions are for the Company’s sole benefit and may be waived by the Company at any time in its sole discretion:

(a) Execution of Documents . Each Purchaser shall have executed such Purchaser’s Execution Page to this Agreement and a Written Consent as set forth in Section 1(b) above and delivered the same to the Company.

(b) Payment of Purchase Price . Each Purchaser shall have delivered, or have had delivered, to an escrow account the full amount of such Purchaser’s Purchase Price, and the escrow agent for such account shall have delivered, or have had delivered, the full amount of all Purchasers’ Purchase Prices to the Company by wire transfer in accordance with the Company’s written wiring instructions.

(c) Representations and Warranties True; Covenants Performed . The representations and warranties of each Purchaser shall be true and correct as of the date when made and as of the Closing Date as though made at that time (except for representations and warranties that speak as of a specific date, which representations and warranties shall be true and correct as of such date), and such Purchaser shall have performed, satisfied and complied with the covenants, agreements and conditions required by this Agreement to be performed, satisfied or complied with by such Purchaser at or prior to the Closing Date.

(d) No Legal Prohibition . No statute, rule, regulation, executive order, decree, ruling, injunction, action or proceeding shall have been enacted, entered, promulgated or endorsed by any court or governmental authority of competent jurisdiction or any self-regulatory organization having authority over the matters contemplated hereby which restricts or prohibits the consummation of, any of the transactions contemplated by this Agreement.

(e) Fairness Opinion . A fairness opinion, in the form substantially similar to fairness opinion attached hereto as Exhibit D, shall have been received by the Company and, as of any Closing Date, shall not have been withdrawn.

8. CONDITIONS TO EACH PURCHASER’S OBLIGATION TO PURCHASE.

The obligation of each Purchaser hereunder to purchase the shares of Series G Preferred Stock for which it is subscribing from the Company hereunder is subject to the satisfaction, at or before the Closing Date, of each of the following conditions, provided that such conditions are for each Purchaser’s individual and sole benefit and may be waived by any Purchaser as to such Purchaser at any time in such Purchaser’s sole discretion:

(a) Execution of Documents . The Company shall have executed such Purchaser’s Execution Page to this Agreement and delivered executed originals of the same to such Purchaser.

(b) Filing of Certificate of Designation . The Certificate of Designation shall have been filed and accepted for filing with the Secretary of State of the State of Delaware and, if requested in writing by any Purchaser, a copy thereof certified by the Secretary of State of the State of Delaware shall have been delivered to such Purchaser.

(c) Delivery of Securities . The Company shall have delivered to such Purchaser duly executed certificates representing the shares of Series G Preferred Stock being purchased by such Purchaser (each in such denominations as such Purchaser shall request), registered in such Purchaser’s name.

(d) Representations and Warranties True; Covenants Performed . The representations and warranties of the Company shall be true and correct as of the date when made and as of the Closing Date as though made at that time (except for representations and warranties that speak as of a specific date, which representations and warranties shall be true and correct as of such date) and the Company shall have performed, satisfied and complied with the covenants, agreements and conditions required by this Agreement to be performed, satisfied or complied with by the Company at or prior to the Closing Date.

(e) No Legal Prohibition . No statute, rule, regulation, executive order, decree, ruling, injunction, action or proceeding shall have been enacted, entered, promulgated or endorsed by any court or governmental authority of competent jurisdiction or any self-regulatory organization having authority over the matters contemplated hereby which restricts or prohibits the consummation of, any of the transactions contemplated by this Agreement.

(f) No Material Adverse Change . There shall have been no material adverse changes and no material adverse developments in the business, properties, operations, financial condition or results of operations of the Company and its Subsidiaries, taken as a whole, since the date hereof, and no information that is materially adverse to the Company and of which such Purchaser is not currently aware shall come to the attention of such Purchaser.

(g) Offer funding . With respect to the initial Closing only, Funds from all Purchasers shall have been received in an escrow account, which total at least $750,000 in the aggregate.

9. GOVERNING LAW; MISCELLANEOUS.

(a) Governing Law; Jurisdiction . This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware applicable to contracts made and to be performed in the State of Delaware. The Company and each Purchaser irrevocably consent to the jurisdiction of the United States federal courts and the state courts located in the County of New Castle, State of Delaware, in any suit or proceeding based on or arising under this Agreement and irrevocably agree that all claims in respect of such suit or proceeding may be determined in such courts. The Company irrevocably waives the defense of an inconvenient forum to the maintenance of such suit or proceeding in such forum. The Company further agrees that service of process upon the Company mailed by first class mail shall be deemed in every respect effective service of process upon the Company in any such suit or proceeding. Nothing herein shall affect the right of any Purchaser to serve process in any other manner permitted by law. The Company agrees that a final non-appealable judgment in any such suit or proceeding shall be conclusive and may be enforced in other jurisdictions by suit on such judgment or in any other lawful manner.

(b) Counterparts . This Agreement may be executed in two or more counterparts, all of which shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other party. This Agreement, once executed by a party, may be delivered to the other parties hereto by facsimile transmission of a copy of this Agreement bearing the signature of the party so delivering this Agreement. In the event any signature is delivered by facsimile transmission, the party using such means of delivery shall cause the manually executed execution page(s) hereof to be physically delivered to the other party within five days of the execution hereof, provided that the failure to so deliver any manually executed execution page shall not affect the validity or enforceability of this Agreement.

(c) Construction . Whenever the context requires, the gender of any word used in this Agreement includes the masculine, feminine or neuter, and the number of any word includes the singular or plural. Unless the context otherwise requires, all references to articles and sections refer to articles and sections of this Agreement, and all references to schedules are to schedules attached hereto, each of which is made a part hereof for all purposes. The descriptive headings of the several articles and sections of this Agreement are inserted for purposes of reference only, and shall not affect the meaning or construction of any of the provisions hereof. Any use of “including” or “includes” shall be deemed to be followed by the phrase, “without limitation” in each case where such phrase does not appear in the text.

(d) Severability . If any provision of this Agreement shall be invalid or unenforceable in any jurisdiction, such invalidity or unenforceability shall not affect the validity or enforceability of the remainder of this Agreement or the validity or enforceability of this Agreement in any other jurisdiction.

(e) Entire Agreement; Amendments . This Agreement and the Certificate of Designation (including any schedules and exhibits hereto) contain the entire understanding of the Purchasers, the Company, their affiliates and persons acting on their behalf with respect to the matters covered herein and therein and, except as specifically set forth herein, neither the Company nor the Purchasers make any representation, warranty, covenant or undertaking with respect to such matters. No provision of this Agreement may be waived other than by an instrument in writing signed by the party to be charged with enforcement, and no provision of this Agreement may be amended other than by an instrument in writing signed by the Company and each Purchaser.

(f) Notices . Any notices required or permitted to be given under the terms of this Agreement shall be in writing and sent by certified or registered mail (return receipt requested) or delivered personally, by nationally recognized overnight carrier or by confirmed facsimile transmission, and shall be effective five days after being placed in the mail, if mailed, or upon receipt or refusal of receipt, if delivered personally or by nationally recognized overnight carrier or confirmed facsimile transmission, in each case addressed to a party as provided herein. The initial addresses for such communications shall be as follows, and each party shall provide notice to the other parties of any change in such party’s address:

(i) If to the Company:

Cortex Pharmaceuticals, Inc.

126 Valley Road, Suite C

Glen Rock, NJ 07452

Facsimile: (201) 493-0887

Attention: Arnold Lippa, Ph.D., President and Chief Executive Officer

with a copy simultaneously transmitted by like means (which transmittal shall not constitute notice hereunder) to:

Drinker Biddle & Reath LLP

500 Campus Drive

Florham Park, NJ 07932-1047

Facsimile: (973) 360-9831

Attention: James M. Fischer

(ii) If to any Purchaser, to the address set forth under such Purchaser’s name on the Execution Page hereto executed by such Purchaser.

(g) Successors and Assigns . This Agreement shall be binding upon and inure to the benefit of the parties and their successors and assigns. Except as provided herein, the Company shall not assign this Agreement or any rights or obligations hereunder. Any Purchaser may assign or transfer the Securities pursuant to the terms of this Agreement and of such Securities, or assign such Purchaser’s rights hereunder to any other person or entity.

(h) Third Party Beneficiaries . This Agreement is intended for the benefit of the parties hereto and their respective permitted successors and assigns, and is not for the benefit of, nor may any provision hereof be enforced by, any other person.

(i) Survival . The representations and warranties contained in this Agreement shall not survive the Closing.

(j) Publicity . The Company shall have the right to approve before issuance any press releases, SEC or, to the extent applicable, FINRA filings, or any other public statements with respect to the transactions contemplated hereby made by any Purchaser, except to the extent such release, filing or statement is required by law. The Company shall be entitled, without the prior approval of the Purchasers, to make any press release or SEC filings or, to the extent applicable, FINRA filings with respect to such transactions as is required by applicable law and regulations (although the Purchasers shall be provided with a copy thereof).

(k) Further Assurances . Each party shall do and perform, or cause to be done and performed, all such further acts and things, and shall execute and deliver all such other agreements, certificates, instruments and documents, as the other party may reasonably request in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated hereby.

(l) Joint Participation in Drafting . Each party to this Agreement has participated in the negotiation and drafting of this Agreement. As such, the language used herein and therein shall be deemed to be the language chosen by the parties hereto to express their mutual intent, and no rule of strict construction will be applied against any party to this Agreement.

(m) Remedies . No provision of this Agreement or any other Transaction Document providing for any remedy to a Purchaser shall limit any other remedy which would otherwise be available to such Purchaser at law, in equity or otherwise. Nothing in this Agreement or any other Transaction Document shall limit any rights any Purchaser may have under any applicable federal or state securities laws with respect to the investment contemplated hereby.

(n) Knowledge . As used in this Agreement, the term “knowledge” of any person or entity shall mean the actual knowledge of such person or the current officers of such entity.

(o) Exculpation Among Purchasers . Each Purchaser acknowledges that it has independently evaluated the merits of the transactions contemplated by this Agreement and the Certificate of Designation, that it has independently determined to enter into the transactions contemplated hereby, that it is not relying on any advice from or evaluation by any other Purchaser.

[REMAINDER OF PAGE LEFT BLANK INTENTIONALLY]

IN WITNESS WHEREOF, the undersigned Purchaser and the Company have caused this Agreement to be duly executed as of the date first above written.

CORTEX PHARMACEUTICALS, INC.

By:
Name:
Title:

PURCHASER:


(Print or Type Name of Purchaser)

By:
Name:
Title:

RESIDENCE:

ADDRESS:





	Telephone:

	Facsimile:

	Attention:

AGGREGATE SUBSCRIPTION AMOUNT:

Number of Shares of Series G Preferred Stock:

Purchase Price ($1,000 per Share):

DISCLOSURE SCHEDULE

Disclosure Schedule

Capitalized terms used in this Disclosure Schedule and not otherwise defined herein have the meaning ascribed to them in the Stock Purchase Agreement with respect to the Company’s Series G 1.5% Convertible Preferred Stock, par value $0.001 per share (the “ Series G Preferred Stock ”).

Section 4(c) – Capitalization table as of June 30, 2012 and rolled forward to October 31, 2013. Amounts as of October 31, 2013 are estimates.

	Estimated October 31, 2013			June 30, 2012
Secured Promissory Note (465,000,000 Korean Won)	$	400,000		$	400,000

Accrued Interest		61,089			-0-

Stockholders’ (deficit) equity:

Series B convertible preferred stock, $0.001 par value; $25,001 liquidation preference; shares authorized: 37,500; shares issued and outstanding: 37,500; shares issuable upon conversion: 3,679		21,703			21,703

Common stock, $0.001 par value; shares authorized:
205,000,000; shares issued and outstanding: 144,041,558 as of August 13, 2012 and estimated at October 31, 2013 and 85,623,663 at June 30, 2012		144,091			85,624

Additional paid-in capital		122,015,018			121,516,230

Accumulated deficit		(126,632,340	)		(122,697,864	)

Total stockholders’ (deficit) equity and secured promissory note (with accrued interest)		(3,990,439	)		(674,307	)

Section 4(e) –

Conflicts and consents – The Company’s current Directors and Officers Policy terminates in the event of a change of control. We anticipate that a closing of the Minimum Amount in this Offering will trigger a change of control. The Company has negotiated a new policy that will take effect upon the termination of the present policy. The Company also has negotiated for a Directors and Officers policy that will cover the period prior to the change of control.

Section 4(f) –

Compliance

Samyang note for 465,000,000 KW (approximately US$ 400,000) was due June 25, 2013 and has not been paid. No request for payment has been made by Samyang. Samyang’s representative resigned from the Company’s Board of Directors on September 30, 2013, and no replacement has yet been named by Samyang.

ii.

On October 10, 2007, Pier Pharmaceuticals, Inc. entered into a license agreement with the University of Illinois (as amended, the “License Agreement”). The Company acquired Pier Pharmaceuticals, Inc., previously known as SteadySleep RX Co., in a merger effective August 10, 2012. The License Agreement gave the Company rights to patents claiming the use of cannabinoids for the treatment of sleep disorders. In addition, the Company has filed patent applications describing a dosage range for the use of dronabinol in the treatment of sleep apnea, as well as for various formulations of dronabinol.

On February 19, 2013, the University of Illinois notified the Company of a default under the License Agreement due to non-payment of a $75,000 milestone fee that had been due December 31, 2012. Under the terms of the License Agreement, the Company had 30 days to cure the default, which it did not do. On March 22, 2013, the Company received a letter from the University of Illinois indicating that the License Agreement had been terminated on March 21, 2013. On the same date as the receipt of the termination letter, newly appointed officers of the Company initiated discussions with the University of Illinois regarding the possibility of extending the cure period or otherwise amending the License Agreement. On April 1, 2013, after considering the Company’s proposals, the University of Illinois informed the Company that, while it believed the License Agreement was terminated, it remained open to negotiating a new license agreement.

Accordingly, the Company and the University of Illinois currently are in discussions regarding the terms of a new license agreement. However, there can be no assurances that a new license agreement will be agreed upon. Regardless of whether such new license agreement is reached, the Company believes that, independent of the License Agreement, it retains its rights of inventorship to the additional patents and patent applications describing a dosage range for the use of dronabinol in the treatment of sleep apnea, as well as for various formulations of dronabinol.

While the Company believes it has sole inventorship of these additional patents, there can be no assurances that the University of Illinois will not pursue other license partners claiming their own rights of inventorship in respect to the same patents. If the University of Illinois were to enter into a new license agreement with a different party or develop the intellectual property on its own, the Company would face direct competition, which could be materially adverse to the Company.

iii.

The Company’s rights to certain of the early AMPAKINE compounds were the subject of license agreements involving patents or patent applications owned wholly by The Regents of the University of California or by the University as a co-owner with the Company. The agreements with The Regents of the University of California have been cancelled. The Company believes that the related patents would have expired before any commercialization opportunity. The Company does not believe this license agreement is material or necessary for the Company’s current drug development plans.

Section 4(g) –

SEC filings

The Company’s periodic reporting obligations pursuant to SEC rules and regulations have been and continue to be delinquent subsequent to June 30, 2012. The Company’s current management, who joined the Company in March and April 2013, cannot make assurances as to the exact time frame in which the Company’s SEC reporting obligations are expected to become current, but currently intends to bring the reporting current by April 2014. At this time, the Company is unable to provide assurances that it will regain current SEC filing reporting status, though that is its intention. As a result, the ability of the Company’s stockholders to utilize SEC Rule 144 for an indeterminate period of time may be adversely affected. The Company currently is not permitted and may not be permitted in the future to, among other things, file and have declared effective registration statements to effect public offerings of its securities.

Section 4(h) –

Transactions with affiliates

To date, Dr. Arnold S. Lippa, the Company’s Chief Executive Officer, has loaned the Company $125,000 and received from the Company demand promissory notes in this amount. At the closing of the Offering, the outstanding principal and interest due on these promissory notes automatically will be converted into the same Securities that are being issued to all other purchasers of the Securities. In connection with such conversion, the Dr. Lippa will receive the same benefits and privileges provided by the Borrower to the other purchasers of the securities. Upon conversion of the principal and accrued interest under these promissory notes, the Company will issue to Dr. Lippa the securities so acquired, and Dr. Lippa will deliver these promissory notes to the Company marked “cancelled.”

Section 4(i) –

Absence of litigation

A former executive officer has requested a hearing with the California Department of Labor.

One vendor has instituted litigation in respect of amounts due and unpaid. Such amounts have been reflected in the Company’s accounts payable and accrued expenses.

Section 4(j) –

Intellectual property

See Appendix 1 at end of Schedule

ii.

see above Sections 4(f)ii and 4(f)iii

Section 4(k) –

Employee Relations

Any material labor dispute or threatened dispute:

Certain of the Company’s former officers and/or directors have asserted formal claims against the Company for unpaid salary and wages, paid time off and severance aggregating $1,326,264 as presented below. Such amounts exclude any interest and attorney’s fees.

Mark Varney - $509,639

Steven Johnson - $327,126

James Coleman - $196,819

Roger Stoll - $292,680

Coleman and Stoll have also asserted that they are owed fully-vested stock options for a total of 5,166,668 shares of the Company’s common stock, exercisable for 10 years at $0.06 per share. In addition, Varney and Johnson are owed an aggregate of approximately $10,000 for consulting services rendered after their employment with the Company terminated. Although the Company has initiated settlement discussions with these parties, no formal agreements have been reached. Subsequent to the completion of this Offering, the Company intends to re-engage with these parties in an attempt to reach mutually agreeable settlement terms. However, there can be no assurances that the Company will be successful in negotiating mutually agreeable settlement arrangements, or in avoiding litigation with some or all of these parties.

ii.

List of any and all amounts due and owing, or allegedly due and owing but disputed, to any current or former employee of the Company:

In addition to the amounts above in Section 4(m)(i), the former Chief Financial Officer, Maria Messinger is owed $118,508. Based upon records available to the current management team and Board of Directors, there are no other amounts owed or alleged to be owed to any other employees.

Section 4(n) –

Directors, Officers and Employees buying stock

Arnold Lippa and affiliates.

Inclusive of the conversion of the $125,000 of demand promissory notes described above, Dr. Lippa and/or affiliated entities intend to purchase up to $250,000 of the Preferred Stock offering on the same terms and conditions as the other investors.

ii.

Mr. Robert N. Weingarten, Company’s Chief Financial Officer and Director

Mr. Weingarten intends to purchase $25,000 of the Preferred Stock offering on the same terms and conditions as the other investors.

iii.

Marc Radin

Marc Radin intends to purchase $25,000 of the Preferred Stock offering on the same terms and conditions as the other investors.

iv.

Compensation with respect to Preferred Stock offering.

Officers, directors, affiliates, and affiliates of officers and directors, will not be compensated with respect to the Offering, directly or indirectly.

APPENDIX 1

1. Patents Assigned to Cortex Pharmaceuticals Inc.

Di-Substituted Amides For Enhancing Glutamatergic Synaptic Responses-PCT/US2008/006271

Country	App. No.	File Date	Patent No.	Issue Date
PCT	PCT/US2008/006271	16-May-2008
Argentina	80102127	19-May-2008
Australia	2008-254960	16-May-2008
Canada	2,685,858	16-May-2008
Chile	14652008	16-May-2008
China	2008-80023572-4	16-May-2008
Eurasia	2009-01546	17-Dec-2009
Europe	2008767737	16-May-2008
India	4322/KOLNP/2009	14-Dec-2009
Indonesia	WO-2009-03208	17-Nov-2009
Israel	202187	16-May-2008
Japan	2010-508435	17-Nov-2009
Korea	10-2009-7025525	7-Dec-2009
Malaysia	PI20094883	17-Nov-2009
Mexico	MX/a/2009/012430	9-Dec-2009
New Zealand	582035	7-Dec-2009	582035	9-Jul-2012
Peru	00856-2008/OIN	19-May-2008
Singapore	2009-07597-9	16-May-2009	156979	31-Aug-2012
Singapore-DIV	2012-03630-7	16-May-2012
South Africa	2009/08899	16-May-2008
Taiwan	97119129	16-May-2008
United States-PROV	60/958,069	2-Jul-2007
United States-PROV	60/930,633	17-May-2007
United States	12/657,908	29-Jan-2010	8,119,632	21-Feb-2012
United States	13/348,171	11-Jan-2012	8,507,482	13-Aug-2013
United States	13/755,210	31-Jan-2013
Vietnam	1-2009-02741	17-Dec-2009

Bicyclic Amide Derivatives For Enhancing Glutamatergic Synaptic Responses-PCT/US2008/009508

Country	App. No.	File Date	Patent No.	Issue Date
PCT	PCT/US2008/009508	8-Aug-2008
Australia	2008-2867445	8-Aug-2010
Brazil	PI0814149-5	8-Aug-2010
Canada	2,695,742	5-Feb-2010
China	2008-80102533.3	2-Dec-2010
Europe	2008795126	8-Mar-2010
Hong Kong	11101753.2	23-Feb-2011
India	749/KOLNP/2010	26-Feb-2010
Indonesia	WOO-2010-00706	3-Mar-2010
Israel	203666	2-Feb-2010
Israel	203667	2-Feb-2010
Japan	2010-520992	10-Feb-2010
Korea	1020107004015	24-Feb-2010
Korea	1020107005366	11-Mar-2010
Malaysia	PI2010000627	7-Mar-2010
Mexico	MX/a/2010/001631	10-Feb-2010	To Be Issued	11-Jun-2013
New Zealand	583823	9-Mar-2010	583823	7-Nov-2011
Russia	2010106975	10-Mar-2010
Singapore	2010-00905-8	8-Aug-2008
South Africa	2010/01691	19-Mar-2010	2010/01691	24-Nov-2010
United States-PROV	60/964,362	10-Aug-2007
United States	12/657,908	29-Jan-2010	8,119,632	21-Feb-2012
United States	12/733,073	19-Jul-2010	8,263,591	11-Sep-2012
United States-DIV	13/557,681	25-Jul-2012

Bicyclic Amide Derivatives For The Treatment Of Disorders
United States	12/657,924	1/29/10	8,168,632	5/1/12

Bicyclic Amide Derivatives For Enhancing Glutamatergic Synaptic Responses-PCT/US2010/000255

Country	App. No.	File Date	Patent No.	Issue Date
PCT	PCT/US2010/000255	29-Jan-2010
Australia	2010-208646	1-Aug-2011
Brazil	PI1005316-6	29-Jul-2011
Canada	2,751,285	29-Jan-2010
China	2010-80015403.3	29-Jan-2010
Eurasia	201101162	2-Sep-2011
Europe	2010736150	10-Aug-2011
Hong Kong	12104459.2	2-May-2012
India	6059/DELNP/2011	9-Aug-2011
Indonesia	WO-2011-03101	29-Jan-2010
Israel	241932	1-Aug-2011
Japan	2011-547981	2-Aug-2011
Korea	102011-7019461	22-Aug-2011
Malaysia	PI2011003494	26-Jul-2011
Mexico	MX/a/2011/00860	08/087/2011
Singapore	201105437.6	29-Jan-2010
South Africa	2011-05817	8-Aug-2011	2011-05817	27-Jul-2012
Ukraine	A2011-10589	29-Aug-2011
United States-PROV	61/206,642	2-Feb-2009
Vietnam	1-2011-02280	29-Sep-2011

Low Dose Cannabinoid Medicaments-PCT/US2011/061490

Country	App. No.	File Date	Patent No.	Issue Date
PCT	PCT/US2011/061490	18-Nov-2011
Australia	2022329623	18-Jun-2013
Brazil	11-2013-012468-7	18-May-2013
Canada	To Be Filed	18-May-2014
Europe	11840786.5	18-Jun-2013
Indonesia	WOO-201302675	18-Jun-2013
India	To Be Assigned	18-Jun-2013
Korea	10-2013-7015798	18-Jun-2013
Mexico	13/05664	18-May-2013
United States-PROV	61/415,331	18-Nov-2010
United States	13/261,662	21-May-2013

2. Patents Licensed to Cortex Pharmaceuticals Inc. from the University of Alberta

Method Of Inhibition Of Respiratory Depression Using Positive Allosteric AMPA Receptor Modulators-PCT/CA2007/001517

Country	App. No.	File Date	Patent No.	Issue Date
PCT	PCT/CA2007/001517	30-Aug-2007
Australia	2007291848	16-Feb-2009	2007291848	26-Apr-2012
Brazil	PI0716375-4	30-Aug-2007
Canada	2,660,431	10-Feb-2009
China	2007-80040363.6	30-Aug-2007
Europe	2007-800542	16-Mar-2009
Hong Kong	9110768	30-Aug-2007
Israel	197334	30-Aug-2007
Japan	2009-525874	26-Feb-2009
Korea	1020097005644	19-Mar-2009
Mexico	MX/a/2009/002180	30-Aug-2007
New Zealand	575648	19-Mar-2009
Norway	20090605	30-Aug-2007
South Africa	2009/00955	30-Aug-2007	2009/00955	28-Apr-2011
United States-PROV	60/824,245	31-Aug-2006
United States	11/847,835	30-Aug-2007	8,039,468	18-Oct-2011
United States	13/233,208	15-Sep-2011
United States	11/877,835	4-Oct-2007	8,007,690	30-Aug-2011

3. Patents in Which Inventorship and Assignment to be Determined After Approval of Claims

Sustained Release Cannabinoid Medicaments-PCT/US2010/057302

Country	App. No.	File Date	Patent No.	Issue Date
PCT	PCT/US2010/057302	18-Nov-2010
United States-PROV	61/262,523	18-Nov-2009
United States	13/474,666	17-May-2012
United States	13/889,252	7-May-2013

4. Patents That Had Been Part of the License with the University of Illinois and That Are Being Discussed as Part of a New License Agreement

Functional Role For Cannabinoids In Autonomic Stability During Sleep-PCT/US2002/010876

Country	App. No.	File Date	Patent No.	Issue Date
PCT	PCT/US2002/010876	8-Apr-2002
Australia	2002-309548	17-Sep-2003	2002-309548	23-Nov-2006
Canada	2,443,105	30-Sep-2003
Europe	2736551.9	24-Sep-2003	13 72 638	4-Nov-2009
Europe-DE	60234245.5		13 72 638	4-Nov-2009
Europe-FR	722027695		13 72 638	4-Nov-2009
Europe-GB			13 72 638	4-Nov-2009
Japan	2002-578942	3-Oct-2003	5093967	28-Sep-2012
United States-PROV	60/281,949	6-Apr-2001
United States-PROV	60/333,599	27-Nov-2001
United States	10/472,136	8-Apr-2002	7,705,039	7-Apr-2010
United States-DIV	12/631,359	4-Dec-2009	8,207,230	26-Jun-2012

EXHIBIT A

CERTIFICATE OF DESIGNATION,

PREFERENCES, RIGHTS AND

LIMITATIONS

SERIES G 1.5% CONVERTIBLE

PREFERRED STOCK

CORTEX PHARMACEUTICALS, INC.

CERTIFICATE OF DESIGNATION,

PREFERENCES, RIGHTS AND LIMITATIONS

SERIES G 1.5% CONVERTIBLE PREFERRED STOCK

PURSUANT TO SECTION 151

OF THE DELAWARE GENERAL CORPORATION LAW

Designation and Amount . The designation of this series, which consists of up to 1,700 shares of preferred stock (which shall not be subject to increase without the written consent of holders the Series G Preferred Stock, as hereinafter defined (each, a “ Holder ” and collectively, the “ Holders ”) holding greater than 50% of the Series G Preferred Stock then outstanding), is the Series G 1.5% Convertible Preferred Stock (the “ Series G Preferred Stock ”) with a par value of $0.001 per share and a stated value of One Thousand Dollars ($1,000) per share (the “ Stated Value ”).

Certain Definitions . For purposes of this Certificate of Designation, in addition to the other terms defined herein, the following terms shall have the following meanings: